

Cite this: *J. Mater. Chem. B*,
2024, 12, 4759

Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders

Runxuan Chu,^{id}^a Yi Wang,^{id}^{*b} Jianglong Kong,^{id}^b Ting Pan,^{ac} Yani Yang^{*a} and Jun He^{id}^{*a}

The liver, a complex and vital organ in the human body, is susceptible to various diseases, including metabolic disorders, acute hepatitis, cirrhosis, and hepatocellular carcinoma. In recent decades, these diseases have significantly contributed to global morbidity and mortality. Currently, liver transplantation remains the most effective treatment for hepatic disorders. Nucleic acid therapeutics offer a selective approach to disease treatment through diverse mechanisms, enabling the regulation of relevant genes and providing a novel therapeutic avenue for hepatic disorders. It is expected that nucleic acid drugs will emerge as the third generation of pharmaceuticals, succeeding small molecule drugs and antibody drugs. Lipid nanoparticles (LNPs) represent a crucial technology in the field of drug delivery and constitute a significant advancement in gene therapies. Nucleic acids encapsulated in LNPs are shielded from the degradation of enzymes and effectively delivered to cells, where they are released and regulate specific genes. This paper provides a comprehensive review of the structure, composition, and applications of LNPs in the treatment of hepatic disorders and offers insights into prospects and challenges in the future development of LNPs.

Received 21st November 2023,
Accepted 22nd April 2024

DOI: 10.1039/d3tb02766j

rsc.li/materials-b

1. Introduction

In 1965, liposomes emerged as an early version of LNPs and became a versatile nanocarrier platform that can transport both hydrophobic and hydrophilic drugs, including small molecular chemical drugs,⁵ antibody drugs,⁶ and nucleic acid drugs.^{7–9} Liposomes represent the first successful translation of nano-drug delivery systems from concept to clinical application.^{10,11} Currently, numerous liposomes have been approved and effectively utilized in clinical practice.^{12,13} Compared to liposomes, subsequent lipid nanocarriers, such as solid lipid nanoparticles and cationic lipid–nucleic acid complexes, exhibited more intricate structures and better physical stability.^{14,15} LNPs offer a valuable carrier system for treating various diseases by encapsulating and delivering nucleic acids to specific locations in the body.^{16,17}

LNP technology enables gene editing and protein replacement. Patisiran/Onpattro[®] was the first RNA interference therapy approved by the Food and Drug Administration (FDA) in


2018.¹⁸ After small molecule drugs and antibody therapeutics were invented, researchers proposed a third generation of treatments, *i.e.*, “smart” nanomedicines.^{19,20} The design of nanomedicines aims to optimize the efficiency of biological processes while minimizing potential adverse effects through targeted drug delivery.^{21–23} Nanomedicine facilitated the realization of gene editing technology, which broadly encompasses the delivery of modified nucleic acids to regulate specific protein expression in cells for treating various diseases. LNPs have been increasingly utilized as versatile platforms for nucleic acid delivery due to their ability to overcome major obstacles in gene therapy, namely, degradation and limited cellular uptake of nucleic acids.²⁴ For example, to prepare vaccines for coronavirus disease 2019 (COVID-19), scientists only needed to determine the sequence of virus-related messenger RNA (mRNA) before encapsulating the mRNA in LNPs.^{25,26} Compared to traditional vaccines, mRNA vaccines are more efficient and safer for patients.^{27,28} In addition to mRNA, LNPs can transport and deliver DNA to produce essential proteins that are deficient or dysfunctional in genetic disorders.^{29,30} Additionally, small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) can be utilized to decrease the production of disease-causing proteins, while clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (CRISPR/Cas9) could be employed to edit or deactivate defective genes.³¹ LNPs based on these innovative therapeutic modalities have the potential to significantly

^a National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, P. R. China.
E-mail: yyn8381@126.com, chinaynhe@163.com

^b Department of Chemistry, Hong Kong Baptist University, Kowloon Tung, Hong Kong SAR, P. R. China. E-mail: yiwang2@hkbu.edu.hk

^c Department of Pharmaceutics School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P. R. China





Scheme 1 LNPs were employed to facilitate gene delivery. The LNPs applications in the treatment of hepatic disorders were reviewed. Adapted with permission.¹ Copyright 2023, Springer Nature. Adapted with permission.² Copyright 2022, Springer Nature. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Adapted with permission.³ Copyright 2021, Springer Nature. Adapted with permission.⁴ Copyright 2022, Elsevier B.V.

revolutionize the treatment of rare genetic and incurable diseases in the future. This article reviews the application of LNPs in liver-targeting treatments and surveys the status of clinical trials of LNPs (Scheme 1).^{32–34}

2. Overview, composition, and formation mechanism of LNPs

All the current FDA-approved LNP formulations, such as BNT162b2, Comirnaty[®] of Pfizer-BioNTech and mRNA-1273, and Spikevax[®] of Moderna, are based on the following kinds of lipids: (1) an ionizable lipid, (2) phospholipids, such as 1,2-distearoyl-*sn*-glycero-3-phosphocholine (DSPC), (3) cholesterol, and (4) a polyethylene glycol (PEG)–lipid conjugate.^{35,36} These constituents facilitated the formation of monodisperse nanoparticles (NPs) and the efficient encapsulation of nucleic acid, while also improving the stability, increasing the cellular uptake, and promoting the endosomal escape of the nucleic acid cargo (Fig. 1(A) and (B)).¹⁶

2.1 Ionizable lipids

The hydrophilic and negatively charged nature of nucleic acids hinder their passive diffusion across the cell membrane.³⁸ However, upon binding to serum proteins, nucleic acids become susceptible to phagocytic cells and endogenous nucleic acid degradation.³⁹ Therefore, delivery systems are necessary to protect nucleic acids from degradation and facilitate their effective uptake by target cells.⁴⁰ Cationic lipids are the most appropriate formulation for addressing these issues, although their cytotoxicity remains a major concern.^{41,42}

To avoid the general safety problem of cationic lipids, scientists have proposed the use of ionizable lipids.⁴³ This type of lipid had an apparent acid dissociation constant (pK_a) below pH 7.0, which allowed the nucleic acids to be efficiently loaded under acidic conditions at pH 4.0 while maintaining a neutral surface charge density at pH 7.4.⁴⁴ This strategy enabled better regulation of the circulation characteristics of LNPs within the physiological system, thereby ensuring optimal biological safety.⁴⁵ The LNPs maintained electrical neutrality in the bloodstream, but upon encountering the acidic environment of






Fig. 1 The mechanism of LNP formation. (A) The preparation of LNPs involved the formation of the compact lipid monolayer vesicles that encapsulated the siRNA under acidic conditions at pH 4.0. As the pH increased to 7.4, more cationic lipids became neutral, reducing the electrostatic repulsion and destabilizing the bilayer structures to facilitate the vesicle fusion. During the process of fusion, PEG-lipid, DSPC, and cholesterol migrated to the outer monolayer of the growing LNPs while the ionizable lipid accumulated in the interior to form an oil droplet phase at its core. Equilibrium was achieved when a sufficient concentration of PEG-lipid in the outer monolayer effectively inhibited the inter-LNP fusion. Adapted with permission.¹⁶ Copyright 2018, American Chemical Society. (B) The LNPs with the ratios of the amount of the amino lipid nitrogen to the amount of the siRNA phosphate (N/P) of 1.1 and 1.5 were observed using cryo-transmission electron microscope (cryo-TEM). Adapted with permission.¹⁶ Copyright 2018, American Chemical Society. (C) Proposed mechanism for Onpatro[®] uptake. Adapted with permission.³⁷ Copyright 2022, Elsevier B.V.

endosomes, the LNPs underwent a positive charge transition that triggered membrane destabilization and subsequent release of nucleic acid cargo (Fig. 1(C)).³⁷ The pH sensitivity of LNPs might explain their efficient cellular uptake, but this could not account for their extensive hepatic accumulation. Although these LNPs lack specific targeting ligands for hepatocytes, they can bind to apolipoprotein E (ApoE) upon entering systemic circulation, thereby promoting endocytosis by hepatocytes.⁴⁶

Over the past two decades, a considerable number of ionizable lipids have been developed and evaluated by researchers to improve the transfection efficiency of LNPs (Fig. 2(A)). [3-(Dimethylamino)-2-octadec-9-enoyloxypropyl] octadec-9-enoate (DODAP) was the first reported ionizable lipid, and 4-(dimethylamino)-butanoic acid (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino) butanoate (DLin-MC3-DMA), an ionizable lipid with a pK_a value of 6.44, was identified from a library of 56 ionizable lipids utilized in the development of Onpatro[®].^{47,48} LNP technology was employed in the

development of nucleic acid vaccines for COVID-19, wherein scientists identified two ionizable lipids with saturated tails and conical structures, namely, ALC-0315 (2-hexyl octylic acid 1,1'-[[[4-hydroxy-2,6-diisopropylphenyl]amino]adipic] acetate) and SM-102 (8-[[[2-hydroxyethyl]-6-[6-oxygen(11 alkyl hexyl)-amino]-1-octylnonyl octylic acid ester]) (Fig. 2(B)).^{49,50}

Jayaraman *et al.* reported that the optimal pK_a range for lipids was 6.2–6.5, which plays a crucial role in facilitating efficient hepatic gene silencing *in vivo* for LNPs (Fig. 2(C)).⁴⁸ Another study compared the gene silencing efficacy of LNPs containing different ionizable lipids, ALC-0315 and MC3, in both hepatocytes and hepatic stellate cells (HSCs). The results demonstrated that ALC-0315-based LNPs achieved potent siRNA-mediated gene silencing in both cell lines. The process for screening ionizable lipids requires extensive experimental verification and continuous optimization.⁵¹ Yu *et al.* reported that the premodification of cationic lipids with aminoglycosides and the utilization of LNPs could enhance the efficiency of mRNA delivery. The modified LNPs could deliver luciferase






Fig. 2 The structure and characteristics of LNPs were elucidated. (A) The ionizable lipids 1,2-dilinoleyloxy-*n,n*-dimethyl-3-aminopropane (DLinDMA) were composed by the headgroup, linker, and hydrocarbon chain. The ionizable lipids and anionic endosomal membrane lipids exhibited a cylindrical shape that facilitated the bilayer packing. When the ionizable and anionic lipids were mixed, the combined headgroup area was reduced compared to the sum of the individual headgroup areas due to the ion pairing. The molecular shape encouraged the nonbilayer phases, similar to the hexagonal H_{II} phase shown here, which could cause membrane fusion or disruption because a bilayer structure could not be maintained. Adapted with permission.⁵³ Copyright 2010, Springer Nature America. (B) The chemical structures of the mentioned ionizable lipids of DODAP, DLin-MC3-DMA, SM-102, and ALC-0315. (C) The pK_a value of LNP was determined through the fluorescence titration using 2-(*p*-toluidine)-6-naphthalene sulfonic acid (TNS). Adapted with permission.⁴⁸ Copyright 2012, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

(Luc) mRNA at a dose of 0.05 mg kg⁻¹, resulting in an average luminescence intensity of 10⁷ (a.u.) in the liver. An engineered tdTomato mouse model was used to demonstrate the potential application of this efficient mRNA delivery system for gene editing.⁵²

2.2 PEGylated lipids (PEG-lipids)

PEG-lipids are an essential component of LNP formulations and account for approximately 1.5% of the total molar percentage.⁵⁴ Lipids contain a hydrophilic PEG polymer and a hydrophobic lipid anchor, in which the lipid domain is deeply embedded in the LNPs while the polyethylene glycol domain extended outwards.⁵⁵ Moreover, PEG-lipids are commonly utilized in liposomal systems to extend the duration of circulation. These lipids function as a physical barrier that hinders the binding of plasma proteins to NPs and prevents the rapid clearance of NPs by the reticuloendothelial system (RES).^{56,57}

It was reported that PEG-lipid-containing LNPs exhibited remarkable stability in buffer at 4 °C for up to three weeks, as evidenced by the particle size, polydispersity index (PDI), zeta potential, and encapsulation efficiency measured during storage.^{58,59} The shelf life of the modified Moderna mRNA

COVID-19 vaccine (Spikevax[®]) from the European Medicines Agency (EMA) is currently known to be 9 months between -25 °C and -15 °C or 30 days at 2-8 °C.⁶⁰ The Pfizer-BioNTech vaccine (Comirnaty[®]) should be stored between -90 °C and -60 °C for up to 9 months or at 2-8 °C for up to 5 days.^{61,62} The transfection efficiency of LNPs was influenced by the proportion of PEG-loaded lipids incorporated in the formulation. Lokugamage *et al.* presented an LNP delivery system designed to efficiently deliver atomization-mediated therapeutic RNA to the lungs. The lipid composition, molar ratio, and structure of the LNPs were systematically optimized. The results revealed that the absence of PEG-lipid constituents in the LNPs had a significant impact on the stability and properties of the dispersions, thereby affecting the transfection efficiency of the LNPs. These findings confirmed the crucial role played by PEG-loaded lipids in LNP formulations.⁶³

2.3 Role of helper lipids

Helper lipids, including cholesterol and phospholipids, were employed to enhance the stability of LNPs during storage and circulation.⁶⁴



2.3.1 Phospholipids. The most widely used phospholipids in LNP formulations are [(2*S*)-2,3-di(octadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate (DSPC) and 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE).⁶⁵ Currently, DSPC remains the exclusive phospholipid utilized in commercial LNP systems. Phospholipids perform multiple functions in LNPs, such as enhancing encapsulation efficiency and promoting stability.^{66,67}

LoPresti *et al.* compared the delivery efficiency of LNPs in which the standard helper lipid DOPE was replaced with different lipids. The findings indicated that the substitution of conventional helper lipids with anionic lipids or cationic lipids would impact the hepatic targeting of LNPs, which could lead to the redirection of LNPs towards the spleen or lung.⁶⁸ In another study, scientists screened a library of 96 LNPs in a high-throughput manner and demonstrated that several formulations containing DOPE exhibited preferential accumulation in the liver. LNPs containing DSPC as a helper lipid were observed to accumulate primarily in the spleen, indicating that LNPs can be tailored for specific purposes based on the choice of helper lipids.⁶⁹ Álvarez-Benedicto *et al.* modulated the phospholipids in LNPs to investigate the roles of helper lipids in LNP formulations. The study indicated that phospholipids containing phosphatidyl ethanolamine (PE) head groups exhibited consistent superiority in delivering mRNA both *in vitro* and *in vivo*. Zwitterionic phospholipids facilitated liver targeting, while negatively charged phospholipids redirected LNPs from the liver to the spleen.⁷⁰

2.3.2 Cholesterol. Cholesterol, a naturally abundant component of cell membranes, is frequently employed as a structural lipid in LNP formulations, typically comprising 20–50% of the overall formulation.⁷¹ The presence of cholesterol enhanced the binding affinity between the PEG–lipid and cationic lipid. Cholesterol plays a pivotal role in enhancing the membrane rigidity of LNPs.⁷²

Patel *et al.* designed a library of LNPs containing hydroxycholesterols and assessed the impact of these compounds on the delivery of mRNA to T cells by exploiting endosomal trafficking mechanisms. The results suggested that replacing 25% and 50% of cholesterol with 7 α -hydroxycholesterol in LNPs led to increases of 1.8-fold and 2.0-fold, respectively, in the delivery of mRNA to primary human T cells *in vitro*, without any additional cytotoxicity or significant impact on the stability of LNPs.⁴

3. Nucleic acid therapeutics

The mechanism of action for nucleic acid drugs differs from that of traditional small molecule drugs. Nucleic acid therapy utilizes RNA or DNA to regulate the expression level of target proteins after gene transcription or before protein translation, thereby employing biological mechanisms to address the chemical constraints of “undruggable” targets.⁷³

The exogenous antisense oligonucleotide (ASO) is an 18–30 nt single-stranded oligonucleotide molecule that can be a heterozygous

single strand of DNA, RNA, or DNA/RNA. Upon cellular uptake, the ASO complements the target sequence and induces mRNA degradation through RNase H1 activity, thereby inhibiting protein expression.⁷⁴ Alternatively, the ASO can achieve selective pre-mRNA splicing and regulate gene translation through steric effects to accomplish disease treatment.⁷⁵

The therapeutic effects of small interfering RNA (siRNA), a 20–25 nucleotide double-stranded RNA molecule, are achieved through posttranscriptional gene silencing. Unlike single-stranded ASOs, siRNAs contain a ‘passenger’ (sense) strand with the same sequence as the target RNA and a complementary ‘guide’ (antisense) strand.⁷⁶ Upon binding to the RNA-induced silencing complex (RISC) in the cytoplasm, siRNAs undergo passenger strand removal, thereby enabling the guide strand to function as a template for precise target recognition. Activated RISCs recognize complementary mRNAs of target genes and induce the degradation of mRNAs.⁷⁷ Therefore, by designing siRNA molecules with specific sequences, researchers can accurately target and degrade specific mRNA molecules, thereby inhibiting the expression of the corresponding proteins.

mRNAs are composed of hundreds or thousands of oligonucleotide molecules and upregulate the expression of target proteins *in vivo*. In the cytoplasm, mRNAs function by binding to ribosomes for the translation of target proteins. These translated proteins can be intracellular, secreted by cells for uptake by other cells, or can specifically interact capable of specific interactions with targets on the cell surface. Despite being unstable both *in vitro* and *in vivo*, mRNA drugs do not require nuclear localization, thus preventing mutations caused by genomic integration.⁷⁸

4. Hepatic-targeted delivery and therapy

4.1 Hepatic delivery

LNPs have been extensively studied for several decades. Like other nanomaterials, which have increased vascular permeability, nanomaterials can accumulate in regions such as tumour sites or areas with inflammation or infection.⁷⁹ This phenomenon is known as the enhanced permeability and retention (EPR) effect.⁸⁰ The liver, the largest abdominal organ, performs at least 500 known physiological processes, such as the synthesis of numerous biochemicals,⁸¹ the detoxification of metabolites,⁸² and the storage of energy.^{83,84} Hepatocytes comprise 80% of the liver by volume, and liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs) and HSCs accounting for only 2.8%, 2.1%, and 1.4%, respectively.⁸⁵

4.1.1 Liver architecture. The hepatocytes, KCs, SECs, and HSCs are organized into lobules, which serve as histological units of the liver. Disse, also referred to as the *peri*-sinusoidal space, physically separates hepatocytes from discontinuous SECs and contains dispersed lipocytes or HSCs. Within the microenvironment of the space of Disse, a dynamic exchange of nutrients, proteins, and waste are exchanged between hepatocytes and blood.



Kupffer cell (KC). KCs can remove foreign particles or red blood cells from the bloodstream through phagocytosis.⁸⁶ KCs constitute only 6.5% of the liver volume, yet they represent 80–90% of the tissue macrophages within the body.⁸⁷ The levels of KCs are abundant in rats aged more than 20 months,⁸⁸ as well as in individuals with alcohol-related liver disease.⁸⁹ KCs play a pivotal role in the pathogenesis of hepatitis, fibrosis, intrahepatic cholestasis and alcoholic liver disease.⁸⁹ The activation of KCs produces proinflammatory mediators, such as prostaglandins, signaling molecules, reactive oxygen species, and others, while preventing liver inflammation.⁸⁷

Sinusoidal endothelial cells (SECs). SECs are considered quiescent in terms of phagocytosis. However, upon KC impairment, the SEC acquires phagocytic competence. Comprising approximately 40% of hepatic cells, the SEC serves as a crucial barrier between the blood and hepatocytes. These intercellular spaces ranging from 50 to 200 nm and aggregate to create sieve plates that enable filtration, facilitating the diffusion of numerous substances while restricting the passage of particles 80 to 500 nm in size.⁹⁰ Deposition of the extracellular matrix (ECM) results causes SECs to thicken, leading to fibrosis. Above all, the SEC plays a pivotal role in regulating haemostasis, inflammatory responses, microcirculation, and immunity.⁹¹

Hepatic stellate cells (HSCs). Eighty percent of the retinoids in the HSC house are found throughout the body. Under normal physiological conditions, HSCs are quiescent.⁹² The activated HSCs function as antigen-presenting cells and promote the expansion of natural killer T cell.⁹³ HSCs stimulate the generation of nitric oxide by secreting fibronectin and vascular endothelial growth factor. Retinol is thus removed from the cell, and HSCs experience morphological alterations. Fibrosis and cirrhosis result from this process, which also causes enhanced proliferation and transdifferentiation of HSCs into fibrogenic myofibroblast-like cells that release collagen scar tissue in addition to fibrogenic and inflammatory cytokines (ECM).⁹⁴

Hepatocytes. Hepatocytes constitute approximately 80% of the liver volume and play a pivotal role in the metabolism of carbohydrates, lipids, and proteins. They are also involved in the secretion of bile, clotting factors, cholesterol, and protein transporters.⁹⁵ Hepatocytes are highly differentiated cells with a high capacity for replication and longevity. Hepatocytes are long-living, highly differentiated cells with a high rate of reproduction. These metabolically active cells effectively break down medications, hormones, and hazardous substances that are easily removed from the body. It is usual to refer to this process as the “first pass effect.” When there is a liver injury, hepatocellular carcinoma, chronic hepatitis, or exposure to specific toxins, there is an extensive expansion of hepatocytes and cellular damage that lasts until cirrhosis.⁹⁶

4.1.2 Liver biological barriers. Upon intravenous administration of LNPs, the size and shape of the particles significantly influence their migration towards vascular walls under physiological flow conditions in blood vessels. The parietal layer of the

hepatic sinusoid consists of endothelial cells and a matrix, which act as a barrier for the entry of substances into liver tissue. As LNPs traverse through the liver along with the bloodstream, they must penetrate the parietal layer of the hepatic sinusoid to access liver tissue. Small spherical particles migrate within an acellular zone while maintaining a considerable distance from endothelial surfaces. This limitation impedes effective accumulation through passive targeting mechanisms as well as active targeting tactics. Additionally, the presence of plasma proteins, platelets, and other cellular components in circulation may compromise the stability of LNPs.⁹⁷ Apart from intravenous injections, other methods of administration to the bloodstream include of subcutaneous injection and distribution by the mucosa of the nose,⁹⁸ skin, or lungs.⁹⁹ There is an additional absorption barrier added by each of these components that needs to be overcome.

Large LNPs pass through the bloodstream and are subsequently taken up by resident macrophages of the mononuclear phagocyte system (MPS). Upon entering the liver, LNPs can be recognized and internalized by KCs, thereby hindering their delivery to target cells. Once LNPs reaches the target cell, they encounter formidable barriers, including cellular internalization and endosomal escape. In addition, size and surface modification affect the route of internalization and intracellular fate. The acidic pH environment of lysosomes and the presence of cytoplasmic nucleases, particularly nucleic acids, pose significant challenges to the maintenance of cargo integrity.^{100,101} However, despite their relatively high delivery efficiency, only 1–4% of the phagocytosed LNPs successfully achieved lysosomal escape.¹⁰²

In addition, LNPs can potentially elicit immune responses, such as inflammatory and cell-mediated immune responses. The high incidence of adverse reactions associated with LNPs could be attributed to their specific route of administration, higher drug dosages, and distinct tissue distribution pattern.¹⁰³ These responses may lead to the clearance or restriction of LNPs in the body.³⁴

4.1.3 Liver-targeted delivery. The incidence of liver diseases has continued to increase over the past few decades, and the development of liver-targeted drugs is a promising approach. Generally, drug targeting can be achieved through passive and active strategies.

Liver passive targeting. Passive targeting utilizes the properties of NPs, such as composition, particle size, and charge, to targeted deliver the drugs to specific areas within the organism. This process involves several mechanisms, such as endocytosis, fusion, adsorption, and material exchange in various tissues and cells, and can be achieved by utilizing capillary interception or leveraging the enhanced capillary permeability exhibited by the disease tissues. The liver's 100–150 nm vascular fenestration, which allows for selectivity towards either hepatocytes and HSCs or SECs and KCs on one side (>100 nm), is the primary factor influencing the passive targeting of liver cells (<100 nm). Apart from these methods, deformable



nanocarriers bigger than 400 nm have the potential to extravasate into the Disse space by forceful extrusion.¹⁰⁴

In some diseases, it is challenging to precisely deliver drugs to specific cell types in the liver through passive targeting. For example, in viral hepatitis or nonalcoholic steatohepatitis (NASH), the designated target cell is the hepatocyte;¹⁰⁵ the KC or endothelial cell is the key target cell in acute liver inflammation;¹⁰⁶ the HSC is the key target cell in liver fibrosis or cirrhosis;¹⁰⁷ the bile duct epithelial cell is the key target cell in primary biliary cirrhosis;¹⁰⁸ and the tumour cell is the key target cell in liver cancer.¹⁰⁹ Consequently, passive targeted drug delivery cannot be deemed selective targeted drug delivery.¹¹⁰

Liver active targeting. Active targeting involves the utilization of NPs as “missiles” to precisely deliver drugs to the desired target site, thereby enhancing therapeutic efficacy. Active targeting techniques offer the potential for targeted therapies and the mitigation of undesired side effects even within an organ.

Endogenous mechanism-mediated active targeting. Following intravenous delivery, serum proteins quickly coat nanoparticles (NPs), forming a coating known as the “protein corona”. This layer controls the biodistribution of NPs within the body and significantly alters their surface characteristics. By selectively adsorbing specific plasma proteins onto the NP surface, researchers can achieve targeted delivery to specific organs.¹¹¹

ApoE is a component of the biomolecular crown that functions as an endogenous targeting ligand and is essential for the physiological clearance of lipoproteins and hepatocellular uptake.¹¹² It is a crucial component that influences LNP-mediated nucleic acid delivery. ApoE, which is predominantly synthesized by hepatocytes and most abundant in the liver, contributes to the preferential accumulation of intravenous LNPs in the liver. LNP delivery systems target hepatocytes through ApoE, which interacts to the low-density lipoprotein receptor (LDLR) expressed on hepatocytes.¹¹³

Martin *et al.* investigated the relationship between the ApoE receptor and LNPs both *in vitro* and *in vivo*. They employed an exogenous ligand known as multivalent *N*-acetylgalactosamine (GalNAc), which has a high affinity for the hepatocyte-expressed asialoglycoprotein receptor (ASGPR). The results validated the viability of incorporating both active and passive targeting strategies for RNAi therapeutics in LNP formulations.¹¹⁴ In another study, small-angle neutron scattering was used by the researchers in conjunction with solvent, cholesterol, and selective lipid deuteration to clarify the composition of LNPs and the distribution of lipid components both in the presence and absence of ApoE. The binding of ApoE caused lipids to redistribute within both the shell and core regions, consequently impacting the internal structure of the LNPs and leading to mRNA release.¹¹⁵

Receptor-mediated active targeting. A ligand with high affinity for the receptor, such as a peptide, protein, antibody, or carbohydrate, can be attached to the surface of LNPs. LNPs can have a ligand, such as a protein, peptide, antibody, or carbohydrate, attached to their surface that has a high affinity

for the receptor. LNPs can be selectively targeted by ligands to recognize specific receptors on the surface of target cells in a precise and efficient manner. This approach can specifically target relevant liver cell types associated with a disease while reducing side-effects on other liver cell types.

Kim *et al.* reported engineered LNPs for the specific delivery of RNA into hepatocytes and LSECs, and they examined the effects of LNP particle size and PEGylated lipid content on ApoE-mediated cellular uptake. The LNPs were modified with mannose moieties to achieve active targeting to LSECs while minimizing nonspecific cellular uptake. The selectivity and potential for actively targeting LSECs in the liver of engineered LNPs with mannose moieties surpassed those of conventional LNPs.¹¹⁶ In another study, researchers constructed a stable nucleic acid lipid particle delivery system loaded with mannose-modified HMGB1-siRNA (mLNP-siHMGB1) to target liver macrophages. The findings demonstrated the effective coadministration of mLNPs-siHMGB1 and DHA for the treatment of NASH.¹¹⁷ Zhang *et al.* prepared pPB peptide-modified LNPs for targeted siRNA delivery to HSCs with the aim of suppressing HMGB1 and treating liver cirrhosis. Anticipatedly, pPB-conjugated LNPs loaded with HMGB1 siRNA efficiently suppressed HSC proliferation, apoptosis, collagen deposition, and survival.¹¹⁸

Lipid composition-mediated active targeting. The lipid composition or structure can be customized to actively target LNPs. For example, Ni *et al.* reported that piperazine-containing ionizable lipids (Pi-Lipids) preferentially deliver mRNA to immune cells *in vivo* without targeting ligands.¹¹⁹ In another study, researchers encapsulated the mRNA encoding CAR in a piperazine-based LNP that targets liver macrophages. In the hepatocellular carcinoma (HCC) mice model, the LNP system significantly enhanced the phagocytic function of liver macrophages, reduced tumour burden, and prolonged survival time.¹²⁰ Qiu *et al.* synthesized a library of lipidoids (N-series LNPs) that contained amide bonds. The *in vivo* results revealed that the N-series LNPs predominantly delivered mRNA to the lungs following systemic administration. Interestingly, O-series lipidoids, which incorporate ester bonds into their tails, tended to specifically deliver mRNA to the liver.^{111,121}

In addition to the changes in ionizable cationic lipids, alterations in helper lipids impact LNP targeting. Roy *et al.* developed an mRNA-loaded LNP delivery system for targeted delivery to the hepatic RES. By replacing DSPC with DSPG in the Onpatro[®] formulation, the surface charge of LNPs were changed from neutral to negative without affecting their performance. In embryonic zebrafish and mouse models, the transformed LNPs significantly enhanced mRNA expression both globally in the liver and specifically within hepatic RES cell subpopulations.²

4.2 Treatments for hepatic disorders

Hepatic disorders have emerged as major causes of morbidity and mortality worldwide in recent decades.¹²² According to the global burden of disease (GBD) project, hepatic disorders,



including acute hepatitis, cirrhosis, and hepatocellular carcinoma, accounted for more than 2 million deaths in 2010 and represented approximately 4% of all global fatalities.¹²³ Despite the progress made in vaccines and antiviral medications, hepatic disorders remain a growing global burden due to several factors, including increased life expectancy, sedentary lifestyles, and overconsumption of food.^{124,125} It is estimated that in China, approximately one-fifth of the population suffers from hepatic disorders,¹²⁶ including hepatitis B virus (HBV), hepatitis C virus (HCV), liver fibrosis,¹²⁷ liver cancer, NASH,¹²⁸ alcoholic hepatic disorders (ALD),¹²⁹ and drug-induced liver damage. The inherent liver-targeting property of LNPs was demonstrated by the preferential accumulation of LNPs within hepatocytes.^{130,131} Scientists have utilized the hepatic targeting capability of LNPs and encapsulated nucleic acids in LNPs for targeted treatments of associated diseases.¹³²

4.2.1 Genetic metabolic disorders. Genetic metabolic disorders are prevalent in the paediatric population.¹³³ Liver dysfunctions resulting from mutations in a single autosomal recessive gene underlie many genetic metabolic disorders, affecting 1 in every 800 live births.¹³⁴ Inherited metabolic disorders cause 15–20% of acute liver failure cases in children,¹³⁵ with a mortality rate ranging from 22 to 65%.^{136,137} Liver transplantation is the sole definitive therapy for most

inherited metabolic disorders.¹³⁸ Recently, LNPs have emerged as promising carriers for mRNA-based therapies and have demonstrated remarkable efficacy in the treatment of genetic metabolic disorders.¹³⁹

Amino acid (AA) metabolism disorders. The maintenance of AA homeostasis is indispensable for all living organisms, as it profoundly influences metabolism and the pathogenesis of diseases.¹⁴⁰ Recently, significant attention has been focused on the role of AAs as crucial signalling molecules in the regulation of energy and metabolic homeostasis.^{141,142} In addition to their involvement in protein metabolism, AAs function as crucial molecular regulators of glucose and lipid metabolism.¹⁴³ The liver serves as the primary site for AA metabolism and harbours a diverse array of enzymes that facilitate this process, resulting in metabolic aberrations in AA that can directly impact hepatic functions.¹⁴⁴

Individuals with fumarylacetoacetate hydrolase (FAH) mutations at birth are susceptible to the development of hepatorenal tyrosinemia type I, which can lead to renal dysfunction, liver failure, neurological impairments, and an increased risk of malignancy.¹⁴⁵ Cheng *et al.* prepared dendrimer lipid nanoparticles (mDLNPs) based on 5A2-SC8 lipids to efficiently deliver FAH mRNA specifically to the liver (Fig. 3(A) and




Fig. 3 Design strategies for mDLNPs that could effectively deliver the FAH mRNA to the liver. (A) Systematic optimization of DLNPs was achieved through the design of experiment calculations. (B) Luc mRNA was loaded in the DLNP to further assess the *in vivo* delivery efficacy of the DLNP. (C) During a one-month therapeutic intervention study, the weights of FAH^{-/-} mice were recorded. Adapted with permission.¹⁴⁶ Copyright 2018, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.



(B)).¹⁴⁶ The mDLNPs effectively produced functional FAH protein, restored normal enzyme activity, stabilized body weight, and extended the survival of FAH^{-/-} knockout mice. The results showed that in a mouse model, 44% of hepatocytes in the liver exhibited high levels of FAH protein. In addition, FAH^{-/-} mice treated with FAH mDLNPs displayed similar levels of total bilirubin (TBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) as wild-type C57BL/6 mice and maintained a normal weight throughout the one-month treatment period (Fig. 3(C)). Another research group evaluated the effectiveness of an mRNA-loaded therapeutic approach in rescuing FAH-deficient mice. Repeated intravenous or intramuscular administration of human FAH mRNA-encapsulated LNPs resulted in the synthesis of FAH proteins in deficient mouse livers and restored normal hepatic morphology and body weight.¹⁴⁷

Phenylketonuria (PKU) is an inborn metabolic condition caused by a defect in the functioning phenylalanine hydroxylase (PAH), which results in the accumulation of phenylalanine (Phe) in the blood and organs of patients. This disease can cause developmental delay, neurological deficits, and behavioural abnormalities. Cacicedo *et al.* used mouse PAH mRNA-loaded LNPs for the treatment of PKU mouse models.¹⁴⁸ After repeated administrations of LNPs, the accumulation of Phe in the serum, liver, and brain rapidly decreased. Truong *et al.* systemically administered human arginase 1 (hARG1) mRNA-encapsulated LNPs to a murine ARG1 knockout model. The findings revealed that the level of hepatic arginase expression and activity were increased, resulting in the reinstatement of ureagenesis in the liver. Compared to the negative control group, the experimental group treated with LNPs exhibited prolonged survival and maintained a normal weight without any evidence of hepatotoxicity. Furthermore, normal levels of ammonia and arginine were detected in the plasma, while the amount of hepatic guanidinoacetic acid, a type of guanidine compound, was reduced.¹⁴⁹

Organic acid metabolism disorders. Organic acid metabolism disorders, also known as organic acidaemia or organic aciduria, are genetic hepatic disorders caused by deficiencies in nutrient metabolism enzymes that lead to the accumulation of carboxylic acids and their metabolites.¹⁵⁰ The primary clinical manifestations include acute acidosis, hyperammonaemia, and toxic encephalopathy in neonates and infants.¹⁵¹

Jiang *et al.* proposed an enzyme replacement strategy for the management of propionic acidaemia (PA). A rare and potentially fatal inherited metabolic disease can be caused by the absence of mitochondrial propionyl-CoA carboxylase (PCC), which consists of six alpha-PCC (PCCA) and six beta-PCC (PCCB) subunits. Scientists have used human PCCA mRNA and human PCCB mRNA-encapsulated biodegradable LNPs to successfully produce functional PCC enzymes in the liver.¹⁵² In another study, a human methylmalonyl-CoA mutase (hMUT) mRNA-loaded biodegradable LNP was developed for the treatment of methylmalonic acidemia (MMA), a metabolic disorder with limited therapeutic options. After LNPs were administered

in two distinct mouse models of MMA, a significant reduction (ranging from 75% to 85%) was observed in the plasma level of methylmalonic acid, while the level of hepatic expression and activity of the hMUT protein increased. Heterozygous MMA-treated mice showed significant improvements in survival and weight gain but exhibited no signs of hepatic toxicity or inflammation.¹⁵³

Glycogen storage disease (GSD). GSD is a congenital genetic metabolic disorder caused by the deficiency of various enzymes involved in glycogen metabolism, resulting in impaired glycogen storage or breakdown.¹⁵⁴ Adequate glucose levels are essential for muscles and organs to properly function. The incidence rate of glycogen storage disorders is approximately 1 in 20 000 to 25 000 newborns.¹⁵⁵ The prevalent types of GSD included types I, II, III, and IV, with type I being the most common. Patients might suffer from life-threatening hypoglycaemia and long-term hepatic complications. Cao *et al.* developed a novel treatment for GSD 1a, a type of GSD I, by utilizing LNPs to encapsulate human G6Pase- α -encoded mRNAs. This approach exhibited excellent tolerability and efficacy upon repeated dosing in a murine model.¹⁵⁶

Hyperbilirubinemia. Crigler–Najjar syndrome (CN1) is a rare disorder that affects bilirubin metabolism, and results from mutations in uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1).¹⁵⁷ The disease is characterized by elevated levels of bilirubin, resulting in jaundice. In one study, Greig *et al.* demonstrated the therapeutic efficacy of human UGT1A1 mRNA-encapsulated LNPs for the treatment of hyperbilirubinemia. The LNPs could effectively deliver mRNA to the liver and hepatocytes (the primary site of UGT1A1 activity) *via* receptor-mediated endocytosis. Repeated administration of the mRNA resulted in a frequency-dependent sustained increase in total bilirubin levels. Forty-two days postadministration, the serum total bilirubin levels in adult UGT1A1 knockout mice returned to normal.¹⁵⁸

Cholestasis. Wei *et al.* developed hAHC4 mRNA-loaded LNPs for the treatment of progressive familial intrahepatic cholestasis (PFIC3). PFIC3 is an incurable rare paediatric hepatic disorder characterized by impaired bile flow and progressive liver damage, and the only current therapeutic option is liver transplantation. The pharmacological effects of this approach were assessed both *in vitro* and in a BALB/c *Abcb4*^{-/-} mouse model, which is susceptible to fibrosis. The results demonstrated that treatment with liver-targeted LNPs led to the re-expression of the functional hAHC4 protein and the restoration of phospholipids that were transported in cultured cells as well as in the livers of PFIC3 mice. Subsequent repeated injections of the LNPs effectively alleviated severe disease-related parameters, including inflammation, ductular reactions, and liver fibrosis, in *Abcb4*^{-/-} mice.¹⁵⁹ The above findings demonstrated the therapeutic potential of LNPs for treating inherited metabolic disorders that affect the liver.

4.2.2 Liver cancers. Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two types of liver



cancers that are the second most common cause of cancer-related death worldwide.¹⁶⁰ Combination chemotherapy is currently the standard treatment for advanced ICC, while combination immunotherapy and multikinase inhibitors are the normal therapies for advanced HCC.¹⁶¹ Despite their effectiveness in improving response rates and overall survival outcomes, these therapies yield suboptimal results. Currently, single-agent kinase inhibitors, such as sorafenib and Lenvatinib, are the first-line systemic therapies for advanced HCC.¹⁶² During the progression of HCC, the proteome secreted by hepatocytes undergoes dynamic changes result from tumorigenesis and also contribute to tumorigenesis. LNPs were utilized as an efficacious delivery system for therapeutic nucleic acids in the treatment of hepatic carcinoma.

Yang *et al.* developed a siRNA-loaded delivery system called cRGD-PSH-NPs, which were made of polyethyleneimine (PSH), egg phosphatidylcholine, cholesterol, DSPE-PEG2000, and survivin siRNA with DSPE-PEG2000-cRGD as the targeting ligand to enhance the specificity. The results demonstrated that compared to the unmodified NPs, the modified NPs exhibited superior gene silencing and antitumour activity in HepG2 cells. Furthermore, the modified nanoparticles demonstrated significant tumour inhibition of 74.71% in HepG2 tumour-bearing nude mice without eliciting any toxicity.¹⁶³ In another study, researchers developed a novel siRNA-loaded delivery system called sTOLP, which consists of multifunctional LNPs modified with the cell-penetrating peptide oleoyl-octaarginine (OA-R8) and transferrin to deliver siRNA. The sTOLP NPs consisted of a protamine-complexed siRNA core, OA-R8, cationic and PEGylated lipids, and transferrin as a targeting ligand. Asymmetrically distributed cationic lipids could enhance the formation of ion pairs that have opposite charges to the lipids in the target membrane, thereby facilitating the endosomal escape of siRNA. Compared to other LNPs, sTOLP demonstrated a remarkable tumour inhibition efficacy of 61.7% *in vivo* and exhibited selective uptake by both hepatocytes and tumour cells in HepG2-bearing nude mice without inducing immunogenicity or hepatic or renal toxicity.¹⁶⁴ Yu *et al.* screened LNPs incorporating lipids containing tris(2-aminoethyl)amine (TREN) and three linoleyl chains, called TREN3, which demonstrated exceptional efficacy in siRNA transfection. Furthermore, the LNP formulation's incorporation of polyunsaturated fatty acids, such as linoleic and linolenic acid, improved the efficiency of siRNA delivery even more. These novel LNPs were found to be efficiently taken up by hepatocellular carcinoma cells in mice.¹⁶⁵

Woitok *et al.* prepared an LNP-based delivery system to enhance the therapeutic potential of c-Jun N-terminal kinase 2 siRNA (siJnk2) for HCC treatment, which plays a crucial role in the inflammatory circuit underlying HCC. The LNP system contained the cationic aminolipid XL52, DSPC, cholesterol, and PEG lipid. The formulation demonstrated efficient hepatic accumulation and effectively suppressed Jnk2 expression in hepatocytes, ultimately resulting in reduced carcinogenesis in an advanced liver cancer mouse model.¹⁶⁶ In another study, researchers developed ultrasmall LNPs (usLNPs) that delivered

both sorafenib and midkine siRNA to treat hepatocellular carcinoma in mice. The usLNPs were composed of a novel fusogenic lipid, YSK05, in addition to a variety of phospholipids. A microfluidic device was utilized to optimize the particle size to 60 nm, aiming to enhance tumour penetration efficiency. The results demonstrated that the novel combination effectively eliminated HCC in mice to 85% at an unexpectedly low dose of sorafenib (2.5 mg kg⁻¹), which could not be achieved through treatment with sorafenib alone. Furthermore, this approach eradicated 70% of sorafenib-resistant HCC in mice, indicating its potential for clinical applications in HCC treatment.¹⁶⁷

Rybakova *et al.* established an *in vitro*-transcribed mRNA-encapsulated LNP system for the *in vivo* delivery of trastuzumab, a monoclonal antibody that targets HER2/ERBB2 and is commonly used for cancer treatment. Compared to the administration of trastuzumab protein, intravenous delivery of LNPs resulted in an improved pharmacokinetic profile for the produced protein and enhanced efficacy in mice bearing tumours. Following administration, the LNPs demonstrated remarkable efficacy in reducing tumour volume and enhancing survival rates in HER2-positive mouse tumour models.¹⁶⁸ In another study, researchers have developed LNPs coencapsulated with anti-microRNA (miRNA) 27 and sorafenib, called G-S27LN. They found a distinctive cationic switchable lipid (CSL3) that was applied to encapsulate miRNA and impart pH-responsive properties to the LNPs. CSL3/DSPC/Chol/DSPE-PEG/DSPE-PEG-MAL, conjugated with the anti-Glypican 3 antibody, in a molar ratio of 40/25/20/10/5 made up the final composition of the lipids. G-S27LN demonstrated a specific affinity for HepG2 cancer cells overexpressing GPC3. In liver cancer mouse models, LNPs significantly suppressed tumour burden and reduced tumour cell proliferation without any observed toxicity.¹⁶⁹ Lai *et al.* reported that interleukin-12 (IL-12) mRNA-encapsulated LNPs could effectively impede the progression of MYC oncogene-driven HCC. Compared to those in the control group, the MYC-induced HCC transgenic mice treated with the mRNA-encapsulated LNPs exhibited increased survival rates and a significant reduction in liver tumour burden, as determined by dynamic magnetic resonance imaging.¹⁷⁰

Wang *et al.* demonstrated the essential role of both C-C-chemokine ligand 2 (CCL2) and C-C-chemokine ligand 5 (CCL5) in the development of liver malignancies. To counteract the immunosuppressive process, a highly potent and specific single-domain antibody called BisCCL2/5i was developed to bispecifically bind and neutralize CCL2 and CCL5. The mRNA encoding BisCCL2/5i was encapsulated in a clinically approved LNP platform containing DLin-MC3-DMA, DOPE, C14-PEG2000 and cholesterol. Combined therapy with BisCCL2/5i mRNA-loaded LNPs and a PD-1 ligand (PD-L1) inhibitor generated a robust antitumour effect and improved survival in syngeneic mouse models of primary hepatocellular carcinoma, liver metastasis of colorectal cancer, and liver metastasis of pancreatic cancer.¹⁷¹ In another study, researchers investigated the effectiveness of a multiplexed dendrimer LNP delivery system for precise gene editing in tumours (Fig. 4(A)). The system






Fig. 4 The designed LNPs (siFAK + CRISPR-LNPs) for the tumour-targeted gene editing. (A) Schematic representation of the tumour targeting mechanisms to enable the double-checkpoint blockade therapy. (B) Triple loading of the FAK siRNA, Cas9 mRNA, and sgRNA into the 5A2-SC8 LNPs was schematically illustrated. (C) The tumour size demonstrated the therapeutic effectiveness of the siFAK + CRISPR-PD-L1-LNPs *in vivo*. (D) Representative whole-body and liver images of the mice treated with different LNPs for 55 days. Adapted with permission.¹⁷² Copyright 2022, Springer Nature America.

utilized 5A2-SC8 as the ionizable amino lipid dendrimer, along with DOPE, PEG lipid, and cholesterol. This approach utilized focal adhesion kinase (FAK) siRNA, Cas9 mRNA, and small guide RNA (sgRNA) to enhance cellular uptake and tumour penetration, resulting in an over 10-fold increase in gene editing efficiency within tumour spheroids by suppressing FAK (Fig. 4(B)).¹⁷² The siFAK + CRISPR-PD-L1-LNPs system effectively mitigated ECM stiffness and disrupted PD-L1 expression *via* CRISPR/Cas gene editing, resulting in significant inhibition of tumour growth and metastasis in a liver cancer mouse model (Fig. 4(C) and (D)).

In one study, researchers reported cationic lipid 2-dioleoyloxy-*N,N*-dimethyl-3-aminopropane (DODMA)-based LNPs for

the delivery of the liver-specific tumour suppressor miR-122 to HCC cells. The system, called LNP-DP1, consisted of DODMA, egg phosphatidylcholine, cholesterol, and cholesterol-polyethylene glycol (Chol-PEG). These findings suggested that Chol-PEG containing LNP-DP1 showed optimal delivery efficiency. This study demonstrated that the systemic delivery of miR-122 *via* LNP-DP1 significantly inhibited the expression of miR-122 target genes in both normal liver and diethylnitrosamine (DEN)-induced liver tumours in miR-122 knockout mice. Furthermore, the use of LNP-DP1 containing miR-122 markedly inhibited the growth of HCC xenografts in a mouse model.¹⁷³ In another study, Wang *et al.* incorporated oleic acid (OA) into the LNP formulation and observed a significant



enhancement in the delivery efficiency of siRNA and miRNA. They formulated a series of cationic LNPs with varying helper lipids, including cholesterol, PCs, and unsaturated fatty acids. For confirmation, miR-122 was chosen and encapsulated in LNPs to demonstrate the hepatic delivery efficacy of LNPs in both tumour cell and mouse models. Compared to Lipofectamine 2000, the OA-incorporated LNPs delivered miR-122 more efficiently, resulting in a 1.8-fold increase in mature miR-122 expression and a 20% decrease in the amount of B-cell lymphoma-w, a target of miR-122. The results indicated that OA-incorporated LNPs exhibit significant potential as RNA-based therapeutic nanocarriers for targeted therapy of hepatic disorders.¹⁷⁴

4.2.3 Liver fibrosis. Liver fibrosis affects millions of individuals globally and can progress to cirrhosis and hepatocellular carcinoma.¹⁷⁵ Despite its significant impact on human health, effective antifibrotic treatments are lacking. The pathogenesis of liver fibrosis is attributed to the excessive deposition of ECM.^{176,177} HSCs, as effector cells in liver fibrogenesis, are a crucial population of resident fibroblasts located between LSECs and hepatocytes.¹⁷⁸ Upon activation, quiescent HSCs undergo transdifferentiation into contractile and proliferative myofibroblasts that secrete ECM components in response to hepatic injury.^{178,179}

Zhang *et al.* utilized pPB peptide-modified LNPs to deliver high mobility group box-1 (HMGB1) siRNA and heat shock protein 47 (HSP47) siRNA, resulting in enhanced therapeutic efficacy for the treatment of liver cirrhosis. The components and molar ratios employed for the preparation of pPB-modified LNPs were as follows: DSPE-PEG-pPB:DLin-MC3-DMA:PEG-DMG:DSPC:cholesterol in a ratio of 2:40:3:10:45. The results showed that the HMGB1-siRNA-encapsulated LNPs exhibited superior therapeutic efficacy for liver cirrhosis in murine models compared to that of the HSP47-siRNA-encapsulated LNPs. LNPs can target HSCs, prevent activation and proliferation, silence HMGB1 gene expression, reduce protein release, suppress the development of fibrosis in the liver, and increase survival time in cirrhotic mouse models through the pPB peptide.¹⁸⁰ Jia *et al.* also prepared stable polypeptide pPB-modified nucleic acid LNPs, pPB-SNALPs, with diameters ranging from 110 to 130 nm. The components used in the preparation included DSPE-PEG-pPB, DLin-MC3-DMA, PEG-DMG, DSPC, and cholesterol. These LNPs were specifically designed for the targeted delivery of HSP47 siRNAs to the liver for the treatment of hepatic fibrosis. Compared to unmodified SNALP, pPB-SNALPs exhibited greater liver distribution and HSC uptake *in vivo*, as well as greater uptake by both LX-2 cells and primary mouse HSCs *in vitro*. Moreover, pPB-SNALPs exhibited an augmented inhibitory effect on thioacetamide-induced hepatic fibrosis in a murine model. These findings suggested that pPB-SNALPs have great potential as drug delivery systems for gene therapy for liver fibrosis.¹⁸¹

Han *et al.* synthesized AA-lipidoids, which are lipidoids functionalized with anisamide (AA) ligands, and identified the highly potent AA-T3A-C12 lipid for targeted RNA delivery to activated fibroblasts (Fig. 5(A) and (B)). The ethanol lipid

solution, comprising AA-T3A-C12, DSPC, C14-PEG, and cholesterol, was rapidly mixed with an acidic aqueous solution containing HSP47 siRNA in a microfluidic device to formulate AA-T3A-C12/siHSP47 LNPs. Compared with MC3-based LNPs, AA-T3A-C12-based LNPs showed superior RNA delivery and transfection efficiency in activated HSCs. In a mouse model of liver fibrosis induced by carbon tetrachloride (CCl₄), AA-T3A-C12 achieved approximately 65% gene silencing of HSP47, resulting in a significant reduction in collagen deposition and hepatic fibrosis (Fig. 5(C) and (D)).¹ The results demonstrated the potential of AA-lipidoids as a targeted antifibrotic therapy against activated fibroblasts. Lawitz *et al.* reported an efficient and safe LNP formulation, BMS-986263, which delivered siRNA molecules that targeted HSP47 for the treatment of advanced fibrosis. This phase 2 study was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986263 once every week for 12 weeks in patients with advanced HCV-related hepatic fibrosis. After treatment, the plasma concentrations of BMS-986263 increased in a dose-proportional manner without any significant accumulation during weekly dosing. Patients with liver fibrosis showed significant improvement.¹⁸²

In one study, cationic lipid C12-200-based LNPs were used to target procollagen α 1(I) siRNA to treat liver fibrosis in mice. The results indicated that the LNPs could target activated HSCs and reduce collagen deposition, thereby impeding the progression of liver fibrosis. The LNP delivery platform demonstrated minimal adverse effects, rendering it a promising therapeutic option for treating fibrotic hepatic disorders.¹⁸³ Qiao *et al.* developed an efficient LNP delivery system that specifically targeted HSCs by encapsulating two siRNAs, collagen I (Co1 α 1) to inhibit collagen synthesis and tissue inhibitor metalloproteinase-1 (TIMP-1) to promote collagen degradation. The hyperbranched lipid-based LNPs were composed of amphiphilic cationic hyperbranched lipids (C15-PA) and the helper lipid Chol-PEG-VA. The functional LNPs exhibited remarkable delivery capability and transfection efficiency *in vitro*. *In vivo*, the dual siRNA-loaded LNPs significantly reduced collagen accumulation in fibrotic mice to levels approaching those of the control group. Repeated administration of LNPs did not cause notable toxicity or tissue inflammation.¹⁸⁴

Yang *et al.* developed biodegradable LNPs loaded with human transcription factor hepatocyte nuclear factor alpha (HNF4A) mRNA and investigated the restoration of hepatic functions in various mouse models of liver fibrosis. HNF4A directly targets and activates paraoxonase 1, thereby regulating macrophages and stellate cells to reduce liver fibrosis. Repeated administration of HNF4A mRNA-encapsulated LNPs exhibited a potent therapeutic effect on four distinct murine models of liver fibrosis induced by hepatotoxins and cholestasis. Based on preclinical evidence, HNF4A mRNA therapy may be a promising strategy for reversing liver fibrosis and cirrhosis.¹⁸⁵ In another study, Hu *et al.* developed an LNP system that encapsulated the relaxin gene and a miR-30a-5p mimic and selectively targeted activated HSCs in fibrotic liver tissue. Researchers previously believed that the antifibrotic peptide hormone relaxin






Fig. 5 Design and validation of the AA-T3A-C12 LNP for the targeted delivery to HSCs for the treatment of liver fibrosis. (A) Preparation of the ligand-tethered lipidoid nanoparticles for the targeted delivery of siRNA to the HSCs in the treatment of liver fibrosis. (B) The AA-T3A-C12/siHSP47 LNP was delivered specifically to activate HSCs for the treatment of liver fibrosis by suppressing HSP47 expression. The PEGs on the surface of the LNPs were removed during the blood circulation *in vivo*, exposing the multivalent anisamide ligands on the surface of the LNPs that strongly bind with the Sigma receptors overexpressed on the activated HSCs for uptake. (C) Macroscopic, histopathological, and biochemical analyses were conducted to evaluate the liver fibrosis. (D) Morphometric analysis of the picosirius red stained areas using ImageJ software. Adapted with permission.¹ Copyright 2023, Springer Nature.

directly reverses hepatic stellate cell activation, thereby facilitating the resolution of liver fibrosis. Upon the uptake of LNPs by activated HSCs, hepatic macrophages undergo a phenotypic transition from profibrogenic to proresolving. Combined gene therapy confirmed synergistic antifibrotic effects in murine models of liver fibrosis.¹⁸⁶

4.2.4 Hypercholesterolemia. The maintenance of cellular and systemic homeostasis relies heavily on the balance of cholesterol metabolism. Disruptions to this delicate equilibrium are closely linked with the pathogenesis of cardiovascular and cerebrovascular diseases, neurodegenerative disorders, and various malignancies. Cholesterol is predominantly synthesized



in the liver through a series of approximately 30 enzymatic reactions. The newly synthesized cholesterol and triglycerides are then incorporated into very low-density lipoprotein (VLDL) for secretion into the bloodstream or storage as lipid droplets within cells.¹⁸⁷ VLDL is converted into low-density lipoprotein (LDL) in the bloodstream, which is subsequently bound and endocytosed by LDL receptors on the cell surface of peripheral tissues. The hydrolysis of LDL releases free cholesterol, which can be transported to other organelles or the plasma membrane to perform its biological functions.^{188,189}

Qiu *et al.* constructed a lipid-based LNP delivery platform, which consisted of 306-O12B, cholesterol, phospholipids (DSPC, DOPE, and DOPC), and DMG-PEG₂₀₀₀, to edit the *Angptl3* genome *in vivo*. In the livers of wild-type C57BL/6 mice, this formulation demonstrated specific and effective *Angptl3* gene knockdown, which also led to significant decreases in the levels of LDL cholesterol and triglycerides.¹⁹⁰ Musunuru *et al.* used LNPs for the efficient and precise modification of disease-related genes in live cynomolgus monkeys. After a single injection of LNPs in the mouse model, the levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL cholesterol simultaneously reduced by approximately 90% and 60% *in vivo*, respectively, and remained stable for at least 8 months.¹⁹¹

Suzuki *et al.* developed a degradable lipid L101, which was incorporated into LNPs that exhibited potent and sustained gene-silencing activity in mice. The LNPs were formulated by combining equal amounts of L101 with the internal standard lipid, following the composition ratio of L101/L021/DSPC/cholesterol/PEG-DMG as 30/30/8.5/30/1.5. The median effective dose of siRNA was approximately 0.02 mg kg⁻¹. The L101-based LNPs underwent rapid hepatic metabolism and exhibited excellent tolerability in rats. A single intravenous administration of the PCSK9-targeting siRNA in cynomolgus monkeys resulted in greater than 90% protein silencing, with a measurable reduction in plasma LDL cholesterol levels of 50%, which persisted for two months.¹⁹² In another study, researchers examined the effectiveness of a library of biodegradable LNPs in delivering ASOs to both human cell cultures and mouse models. LNPs based on three lipids, namely, 113-O14B-3, 113-O16B-3, and 306-O12B-3, were identified as effective vectors for delivering GFP-silencing ASOs to cells expressing GFP, and helper lipids, such as cholesterol, DOPE, and PEG lipid, were added to the formulation. Compared to Lipofectamine 2000, the LNPs demonstrated superior delivery efficiency and exhibited lower cytotoxicity *in vitro*. Subsequently, the effectiveness of these LNPs in facilitating PCSK9 mRNA knockdown through the delivery of the PCSK9-silencing ASO to the mouse liver was evaluated.¹⁹³

Tadin-Strapps *et al.* developed a novel mouse model that was genetically modified to carry a single copy of the human CETP transgene and a single copy of an LDL receptor mutation. Compared to normal mice, the novel model showed elevated levels of plasma LDL cholesterol even when a low-fat diet was consumed. The six ApoB siRNA sequences were encapsulated in the LNP system, which contained the cationic lipid Clin-DMA, cholesterol, and PEG-DMG. LNP formulation effectively

induced hepatic ApoB mRNA knockdown in a mouse model, resulting in significant reductions in the expression of serum ApoB proteins and fatty acid-related genes and sustained decreases in the levels of serum total cholesterol, triglycerides, and LDL.¹⁹⁴

Nonalcoholic steatohepatitis (NASH). NASH is a hepatic lipid metabolism disorder caused by nonalcoholic and toxin-related factors.¹²⁵ The disorder initially begins with the accumulation of fat in hepatocytes, progressing to steatohepatitis, cirrhosis, and ultimately hepatocellular carcinoma. Cholesterol was identified as an important molecule involved in this process.¹⁹⁵

Rizvi *et al.* reported a highly efficient and safe LNP delivery system composed of nucleoside-modified mRNA loaded with hepatocyte growth factor (HGF) and epidermal growth factor (EGF) mRNA. The *in vitro* results demonstrated that LNPs could efficiently transfect all hepatocytes in the liver, including endothelial cells and KCs. Furthermore, HGF mRNA-loaded LNPs demonstrated remarkable efficacy in promoting hepatocyte proliferation. In a murine model of chronic liver injury resembling NASH, the codelivery of HGF and EGF mRNA *via* LNPs significantly improved hepatic steatosis and accelerated the restoration of liver functions.¹⁹⁶ In another study, researchers employed a targeted LNP delivery system modified with the mannose receptor for the delivery of the HMGB1 siRNA mLNP-siHMGB1 and coadministered docosahexaenoic acid (DHA) for NASH treatment (Fig. 6(A)).¹⁹⁷ mLNP-siHMGB1 was prepared using DSPE-PEG-Man, DLin-MC3-DMA, PEG-DMG, DSPC, and cholesterol. The specific targeting of macrophages *via* mannose receptors by mLNP-siHMGB1 effectively silenced the HMGB1 gene and reduced HMGB1 protein release in the liver (Fig. 6(B) and (C)). This process led to the modulation of liver macrophages towards an anti-inflammatory M2 phenotype, resulting in the alleviation of hepatic lobular inflammation and bullous steatosis in the NASH mouse model (Fig. 6(D)). Moreover, hepatic function in NASH model mice was restored following 8 weeks of combined treatment with mLNPs-siHMGB1 and DHA.

Homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia (FH) is an inherited disorder resulting from mutations in key genes involved in LDL catabolism, leading to elevated levels of LDL cholesterol. HoFH is clinically characterized by the presence of multiple xanthomas and tendon xanthomata, as well as a predisposition to the early onset of atherosclerotic cardiovascular disease.^{198,199}

Kasiewicz *et al.* developed an LNP formulation delivery system loaded with adenine base editor mRNA and gRNA that targets ANGPTL3. LNPs employ GalNAc as a ligand to specifically target the liver. In the cynomolgus monkey model of HoFH, after treatment with the formulated LNPs, the levels of the ANGPTL3 protein in the whole liver and blood of the cynomolgus monkey were reduced by approximately 60% and 94%, respectively, whereas the standard LNPs yielded minimal editing. Moreover, the editing efficiency achieved by the formulated LNPs in the wild-type model was comparable to that






Fig. 6 The treatment of NASH can be achieved by targeting at the mannose receptor pathway. (A) The LNP-siHMGB1 and mLNP-siHMGB1 exhibited spheroidal structures in TEM images. (B) The efficacy of LNP-siHMGB1 and mLNP-siHMGB1 in gene silencing. (C) After intravenous injection, the fluorescence intensity of the liver was significantly higher in the mLNP-siHMGB1 group (on the right) than the LNP-siHMGB1 group (on the left). (D) The hepatic steatosis and liver inflammation were effectively ameliorated following the treatment with mLNP-siHMGB1, as evidenced by the oil red O staining, HE staining, and immunohistochemical analysis of the liver tissues along with the corresponding quantitative results. Adapted with permission.¹⁹⁷ Copyright 2022, Elsevier B.V.

achieved by the unmodified LNPs. Thus, a potent new tool was provided for the efficient *in vivo* delivery of nucleic acid.²⁰⁰

4.2.5 Liver injury and hepatitis

Acute liver injury. Acute liver injury is a condition in which the liver becomes inflamed due to factors such as drug toxicity, viral infection, excessive alcohol consumption, immune response, and radiation damage.²⁰¹ Inflammation often accompanies acute liver injury, resulting in hepatocyte damage and apoptosis as well as elevated levels of transaminases in the blood that can impair normal hepatic functions.²⁰²

Kawase *et al.* developed biodegradable LNPs based on asymmetric ionizable lipids, which included the ionizable lipids L120, DSPC, cholesterol, and PEG-DMG. These LNPs demonstrated both high potency and excellent tolerability. These LNPs were encapsulated in siRNA targeting interferon regulatory Factor 5 (Irf5), which was subsequently assessed for its anti-inflammatory efficacy in mice. *In vitro* studies demonstrated that LNPs could be taken up by tissue-resident macrophages, particularly liver macrophages. The results indicated that compared to the control group, the mice injected with the



Irf5 siRNA-encapsulated LNPs exhibited significantly lower levels of serum AST, ALT, and inflammatory cytokines.²⁰³ Yin *et al.* developed a novel delivery system that incorporated glycyrrhizic acid (GA) and polyene phosphatidylcholine (PPC) into LNPs, along with DOTAP, DSPE-PEG, and cholesterol. The modified LNPs were designed to enhance cellular uptake, promote gene silencing efficacy, increase siRNA stability, and reduce cytotoxicity. Subsequently, it was discovered that modified LNPs loaded with nuclear factor kappa-B (NF- κ B) siRNA can mitigate acute liver injury, as supported by the results of histological examination, haematological analysis, and cytokine profiling. These findings suggest that LNP formulations are valuable tools for investigating macrophage function *in vivo* and hold promise as potential therapeutic agents for inflammatory diseases in the future.²⁰⁴

Hepatitis B virus (HBV). Sato *et al.* reported that the incorporation of GalNAc into LNPs could effectively reduce hepatotoxicity, particularly when a significant amount of LNPs was accumulated in the liver. Furthermore, the LNP system was encapsulated with YSK13-C3/cho/DSG-mPEG2k/GalNAc3-PEG2k-DSG. In a chimeric mouse model of HBV infection, the administration of LNPs resulted in a significant reduction in both the amount of HBV genomic DNA and relative antigens without indication of toxicity.²⁰⁵ In another study, an advanced mRNA-LNP drug encoding three anti-HBsAg antibody genes, G12-scFv, G12-scFv-Fc and G12-IgG, was developed for the treatment of HBV. The LNP formulation was prepared using SM-102, DSPC, cholesterol, and DMG-PEG2000. The results showed that the injection of a single dose of LNPs containing both G12-scFv-Fc mRNA and G12-IgG mRNA significantly reduced the serum HBsAg level in treated mice within 30 days.²⁰⁶

Hepatitis C virus (HCV). Dallas *et al.* utilized short synthetic shRNA (sshRNA)-encapsulated LNPs to silence the expression of genes associated with the HCV internal ribosome entry site. LNPs consisted of cholesterol, DPPC, PEG-C-DMA, and the cationic lipid DLinDMA at a molar ratio of 34.3 : 7.1 : 1.4 : 57.1. *In vivo* imaging demonstrated efficient hepatic uptake and sustained retention of sshRNA in the liver, with a half-life of approximately 3 weeks for clearance after a single administration. These results suggested that sshRNA-loaded LNPs show promise as therapeutic agents for HCV.²⁰⁷

4.2.6 Other related genetic diseases

Haemophilia A (HA) and Haemophilia B (HB). Haemophilia is a hereditary bleeding disorder caused by an abnormal gene that encodes a coagulation factor, resulting in spontaneous or prolonged bleeding after minor injuries. Haemophilia is an X-linked recessive haemorrhagic disorder, predominantly occurs in male patients and is rare in female patients. Patients with HA and HB lacked coagulation factor VIII (FVIII, F8I22I) and coagulation factor IX (FIX, F9Mut), respectively.²⁰⁸

Han *et al.* developed and optimized LNPs for the efficient delivery of both Cas9 mRNA and a single guide RNA targeting antithrombin (AT) to the liver.²⁰⁹ LNPs were formulated using 246C10, DOPE, cholesterol, and PEG-ceramide (Fig. 7(A)). The endogenous regulator AT negatively modulates the generation

of thrombin. From the results obtained in the HA and HB mouse models, it was observed that the bleeding-associated phenotypes were restored without liver-induced toxicity (Fig. 7(B)–(D)). Furthermore, notable immune reactions against Cas9 were observed, confirming the safety and efficacy of LNP-mediated CRISPR-Cas9 delivery as a sustainable approach for haemophilia therapy. In another study, a formulation of NP was reported for the delivery of two distinct mRNA transcripts encoding human erythropoietin (hEPO) and the factor IX (hFIX) protein. This formulation contained the cationic lipidoid C12-200, DOPE, cholesterol, and DMG-PEG2K. The dose-dependent production of proteins from each mRNA construct was observed *in vivo*. Subsequently, an increase in haematocrit was observed in the mouse model, indicating that exogenous mRNA-derived proteins were preserved. The protein remained at high levels ($\mu\text{g mL}^{-1}$) and was persistently secreted one week after injection. The activity of the protein was confirmed through pharmacodynamic measurements and therapeutic interventions in an HB disease model.²¹⁰ Chen *et al.* employed FVIII mRNA-encapsulated LNPs for the treatment of HA. The luminescent signal of the LNPs was primarily observed in the liver 4 h after intravenous injection of the IVIS, confirming the efficacy of LNP-mediated hepatic targeting. Subsequently, HA mice were administered LNPs carrying various variants of human FVIII mRNAs, resulting in rapid and sustained expression of the FVIII protein. These enduring treatment strategies hold great potential for treating patients with both HA and HB.²¹¹

Transthyretin amyloidosis (ATTR). ATTR disease is a life-threatening condition characterized by the hepatic production of misfolded TTR proteins, which progressively accumulate in nerve and cardiac tissues. The inheritance pattern of ATTR amyloidosis follows an autosomal dominant pattern, and its clinical phenotype is distinguished by either amyloid polyneuropathy or cardiomyopathy. Following the onset of symptoms, patients with amyloid cardiomyopathy typically have a survival time of 2 to 6 years, while those suffering from amyloid polyneuropathy without cardiomyopathy usually have a life expectancy of 4 to 17 years.^{212,213}

Finn *et al.* reported the development of an LNP-mediated delivery system for CRISPR/Cas9 editing *in vivo*, resulting in the knockdown of more than 97% of mouse TTR proteins. The knockdown persisted for at least 12 months. This delivery system contained the biodegradable lipid LP01, the accessory lipid PEG-DMG, Cas9 mRNA, and sgRNA. The efficacy of the LNP formulation was also shown in a rat model, in which the formulation effectively delivered the CRISPR/Cas9 components to reduce the levels of the TTR serum protein. These findings underscore the potential of this platform as an efficient genome editing tool.²¹⁴ In another study, researchers demonstrated that ApoE was an important mediator of TTR silencing using Patisiran/Onpattro[®], which was the first siRNA-loaded LNP approved for clinical use in patients with ATTR amyloidosis. The results showed that patisiran could efficiently reach liver cells through binding to ApoE. Although ApoE polymorphisms might affect its binding to hepatic receptors, the effectiveness of patisiran remains unaffected.²¹⁵






Fig. 7 Enhanced haemophilia therapy through the LNP-mediated CRISPR-Cas9 delivery. (A) The LNPs were formulated using a microfluidic mixing system for *in vivo* gene delivery. (B) Simplified schematic illustrated *in vivo* gene targeting using the LNP-CRISPR-mAT. (C) The liver tissue of F8^{I221} and F9^{Mut} exhibited average indel frequencies of 22% and 38%, respectively. (D) Red blood cells (RBC) in the interstitial liver tissue were quantified using the immunofluorescence staining to detect the autofluorescence signals at 470 and 540 nm, with the black triangles marking their location on the H&E-stained liver tissue. Adapted with permission.²⁰⁹ Copyright 2022, National Academy of Sciences.

5. The challenges of LNP technology

Despite the promising laboratory results, several challenges must be overcome before LNP technology is successfully translated into real-world applications.

The homogeneity and size of the NPs are crucial parameters that need to be regulated. Researchers have shown that the size of NPs significantly influences drug pharmacokinetics by influencing the *in vivo* half-life,²¹⁶ tissue penetration,²¹⁷ and organ-specific absorption.²¹⁸ In comparison to traditional preparation methods, the microfluidic methodology has been designed to synthesize LNPs with smaller particle sizes, a more homogenous distribution, increased batch-to-batch repeatability, and enhanced encapsulation effectiveness of nucleic acid medicines.^{219–221} From

medication discovery to clinical application, scalable synthesis of LNPs with uniform particle sizes and size distributions is still a significant problem.^{222–224} Two approaches have been put forth to do LNP synthesis at a better throughput: channel size enlargement and parallelization.

By implementing numerous mixing channels in parallel, the parallelization technique increases the total flow rate to a substantially higher level than that of a single mixing channel. This approach significantly reduces development costs by optimizing parameters, such as flow rate ratios and lipid concentrations, using only one mixing channel. To ensure consistency and stability across all channels, the parallelization approach requires extensive advanced manufacturing and engineering methods.^{225–227}



The channel-size enlarging method achieves greater injection volume and productivity by expanding the size of a single microfluidic channel.^{222,228} This method simplifies the equipment manufacturing process and increases the stability and reliability of production. It is difficult for a single mixer to synthesize LNPs with consistent properties at different flow rates. Researchers have improved upon the channel size enlarging method and developed an equidistant channel size enlarging method. After applying this improved method to inertial flow mixers with the same structure but different channel sizes, batch synthesis of LNPs with consistent performance can be achieved by controlling the flow resistance.²²⁹

The preparation of LNP formulations remains challenging due to potential issues such as the aggregation, leakage, and fusion of LNPs and susceptibility to degradation of the encapsulated mRNA and siRNA. For the stability of LNPs, while stable lipids can be incorporated into LNPs to maintain short-term stability, long-term storage and extended shelf life of the product are often achieved through freezing. The instability of mRNA-LNPs at 4 °C, which is often attributed to the inherent instability of the mRNA payload rather than the LNP system, is a challenge in this field.^{230,231} For example, the Moderna COVID-19 vaccine must be stored at −20 °C, whereas the Pfizer vaccine can be preserved for up to six months in an ultralow temperature freezer at −70 °C but only for five days in a refrigerator at 2–8 °C. Inadequate storage conditions might result in increased transportation expenses, whereas temperature fluctuations could compromise the quality of the product. Therefore, further investigation of the improvement in stability is necessary to eliminate the need for cold chain transport. Clinical trials testing nonfrozen and lyophilized preparations are underway. (NCT05137236, NCT05085366, NCT04816669) In one study, researchers evaluated the influence of pH, temperature, and lyophilization on LNP efficacy in HeLa cells. Under pH 7 aqueous conditions, the LNPs were more stable when stored at 2 °C for 150 days than when stored in a −20 °C freezer or at room temperature. Although aggregation and loss of efficacy were observed in LNPs subjected to freeze–thaw cycles, their stability was maintained when cryoprotectants, such as trehalose and sucrose, were used.²³² The research results of Packer *et al.* indicate that the presence of electrophilic impurities of ionizable cationic lipid components is a reason for the instability of LNPs. The formation of lipid-mRNA adducts will reduce the activity of the mRNA-LNP product, and impurities introduced during the production process may affect the stability of the vaccine even under refrigerated conditions. Therefore, it is crucial to monitor and control the formation of lipid adducts during the research, development, and manufacturing of LNP-formulated nucleic acid products.²³³

6. Limitations of the present LNP technology

It has been shown that LNPs are both powerful and secure preventative vaccines as well as efficient delivery systems for therapeutic treatments. It is difficult to evaluate the nucleic

acid payload distribution and capacity of LNPs, nevertheless. To analyze the payload distribution and capacity of mRNA LNPs, Li *et al.* devised a multicolor fluorescence spectroscopic technique that included a fluorescence coincidence analysis, a quantitative fluorescence deconvolution algorithm, and a single-molecule detection (SMD) platform. Understanding the links between structure, property, and function in future delivery systems requires knowledge of this information.²³⁴

6.1 Immune stimulation

Identifying the amount of nucleic acid in LNPs enables scientists to better determine the injection dosage and the quantity of lipids used, and excessive amounts of nucleic acid can result in a range of adverse reactions. For instance, reported immune responses to COVID-19 vaccines include allergic reactions and autoimmune disorders. The CDC reported that there were roughly five occurrences of deadly anaphylaxis for every million vaccination doses given.²³⁵ Myocardial and immune thrombotic thrombocytopenia,^{236,237} IgA vasculitis,²³⁸ and autoimmune diseases were among the adverse effects to COVID-19 vaccinations that might occur.^{239,240} Modulating the immune response to LNPs could be achieved through three strategies: (1) manipulating the composition and characteristics of LNPs; (2) adding an adjuvant; and (3) adjusting the administration method.

Researchers can modify the physicochemical properties of LNPs by adjusting the formulation procedure. The four lipids can be changed, additional ingredients can be added, and the composition ratio of each lipid can be changed during the LNP formation process. The characteristics of LNPs might be affected by even minute variations. The size of LNPs in the formulation, for example, is altered by varying the formulation rate or the PEG molar ratio.²¹⁸ Phospholipids could be added to or substituted for charged lipids to change the charge of lipoproteins.²⁴¹ Moreover, PEG lipids can be modified using certain methods.²⁴²

The inclusion of adjuvants improves the efficacy of LNPs, which stimulate innate immune responses and establish a localized immunocompetent environment at the injection site, thereby modifying the nature, strength, and efficacy of adaptive immune responses.²⁴³ For example, before Onpatro is administered, it is necessary to administer acetaminophen, glucocorticoids, and H1/H2 blockers to manage potential immune reactions during infusion.³⁴ Apart from merely incorporating an adjuvant, scientists have also produced ionizable lipids that serve this purpose.²⁴⁴ Imidazole lipid (DOG-IM4), a new immunostimulatory ionizable lipid structure, was produced in one study. The components of DOG-IM4 were an imidazole-based ionizable head group, a dioleoyl lipid tail, and a polyoxyethylene linker that connected the head and tail. The outcomes showed that improving immunization was caused by the imidazole head group of lipids.²⁴⁵

LNPs are administered by a variety of techniques, including intramuscular (IM), intradermal (ID), subcutaneous (SC), intravenous (IV), and intranasal (IN).^{246–250} Researchers discovered that distinct routes of administration had synergistic effects in addition to merely comparing the routes of delivery. Mao *et al.*



Table 1 LNP technology is in clinical trials for siRNA delivery (clinicaltrials.gov)

Name	Indication	Target	Administration route	Phase	Start years	NCT ID
ALN-TTR02	TTR	TTR	i.v.	III	2019	NCT03997383
BMS-986263	NASH	HSP47	i.v.	II	2021	NCT04267393

created the “prime (IM) and spike (IN)” vaccination strategy, which uses unadjuvanted IN to activate mucosal immunological memory in the respiratory system by leveraging preexisting immunity brought on by primary IM immunization. The mice with incomplete vaccination showed protection against deadly SARS-CoV-2 infection, enhanced systemic immunity, and robust resident memory B and T-cell responses in the prime and spike groups as compared to groups that received only IM or IN injections, the researchers showed.²⁵¹

6.2 Targeting ability

In most instances, upon injection into the bloodstream, LNPs undergo spontaneous adsorption of ApoE onto their surface, leading to hepatic accumulation,²⁵² but excessive liver homing of LNPs remains a drawback. Technologies that target the extrahepatic delivery of LNPs facilitate the precise administration of therapeutics to specific cells or tissues. The current options for overcoming the limitations of LNPs in liver targeting include modifying the administration route and adjusting the lipid composition.

The biodistribution of LNPs can be significantly influenced by the administration route. Many studies have shown that the IM and SC routes can be utilized for delivering therapeutics to lymph nodes, which are primarily inhabited by antigen-presenting cells (APCs), T cells, and dendritic cells (DCs).²¹⁷ The term “pulmonary administration” refers to the direct delivery of medications to the lungs, including inhalation and IN methods. Additionally, this approach can get around the problem of KCs’ cellular uptake of LNPs during systemic circulation.²⁵³

It is possible to influence tissue tropism after intravenous injection by merely changing the components of LNPs. Because of their differing affinities for ApoE, researchers found in one study that LNPs carrying DSPC as helper lipids concentrated in the spleen whereas LNPs containing DOPE accumulated in the

liver.²⁵⁴ Chen *et al.* combined selective organ targeting (SORT) molecules with the four traditional components of LNP to accomplish extrahepatic distribution.²⁴¹ The biodistribution of LNPs was impacted by interactions between the SORT molecule’s charge and serum proteins. The tropism of mRNA/LNPs from the liver to the spleen and lung was changed by the addition of anionic and cationic lipids, respectively. Therefore, to create innovative delivery materials that target organs, it is essential to ascertain how particular proteins in serum interact with LNP components.

7. Clinical trials

LNPs are a widely utilized delivery system for the safe and effective transport of nucleic acid drugs. To date, three nucleic acid drugs assisted by LNPs, namely, the ATTR siRNA drug Patisiran/Onpattro[®] from Alnylam, the mRNA vaccine BNT162b2 from Pfizer/BioNTech, and the mRNA vaccine mRNA-1273 from Moderna, have been approved. Compared with other nucleic acid delivery systems, LNPs exhibit superior advantages, including a high encapsulation efficiency of nucleic acids, efficient cell transfection, strong tissue penetration with low cytotoxicity and immunogenicity. The diverse biological roles of RNAs have facilitated their application in various therapeutic contexts in the liver, many of which are undergoing clinical evaluation. Tables 1 and 2 present a summary of recent clinical trials of siRNA-loaded LNPs and mRNA-loaded LNPs, respectively.

8. Summary and outlook

With advancements in nucleic acid drugs and cell pathogenesis genetics, targeted therapy for various human diseases at the gene level has become feasible. After 50 years of development,

Table 2 LNP technology is in clinical trials for mRNA delivery (clinicaltrials.gov)

Name	Indication	Target	Administration route	Phase	Start years	NCT ID
mRNA-4157	Solid tumors	Personalized neoantigens	i.m.	I	2017	NCT03313778
NTLA-2001	Transthyretin amyloidosis-related cardiomyopathy (ATTR-CM)	ATTR	i.v.	I	2020	NCT04601051
mRNA-3927	Propionic acidemia (PA)	Alpha and beta subunits of PCC	i.v.	I/II	2021	NCT04159103
NTLA-2002	Hereditary angioedema (HAE)	HAE	i.v.	I/II	2021	NCT05120830
WGI-0301	Solid tumors	Akt-1	i.v.gtt	I	2022	NCT05267899
ARCT-810	Ornithine transcarbamylase (OTC) deficiency	OTC	i.v.	II	2022	NCT05526066
OTX-2002	HCC and other solid tumors	MYC	i.v.	I/II	2022	NCT05497453
mRNA-3745	GSD	GSD1a	i.v.	I	2022	NCT05095727

i.v.: intravenous injection; i.m.: intramuscular injection; i.v.gtt: intravenous drip.



significant breakthroughs have been achieved in the LNP drug delivery system, which is now widely regarded as the most effective system for delivering nucleic acid drugs.

In this review, we provide an overview of the potential therapeutic applications of LNPs in liver-related diseases. Although researchers have been exploring LNP technology for a decade, only one RNA-based therapeutic (Patisiran/Onpattro[®]) targeting hepatic disorders has been approved for commercialization in more than 30 ongoing clinical trials. This milestone marks the successful convergence of nucleic acid nanomedicine and biomedicine. LNPs present certain advantages over alternative delivery systems. However, further research is needed to enhance long-term safety, optimize immune stimulation, improve delivery volume, and target other organs.

In addition to the applications outlined in this article, LNP technology has been widely applied across various fields, including medical imaging, cosmetics, nutrition, agriculture, and nanoreactors. With the emergence of new lipid materials and advancements in methodologies, LNPs are expected to usher in a new wave of enthusiasm.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

We would like to thank the members of the Novel Injectable Drug Delivery Laboratory of the National Advanced Medical Engineering Research Center for their contribution to this work. This work was supported by a grant from the Science and Technology Commission of Shanghai Municipality (23SA41900200).

References

- X. Han, N. Gong, L. Xue, M. M. Billingsley, R. El-Mayta, S. J. Shepherd, M.-G. Alameh, D. Weissman and M. J. Mitchell, *Nat. Commun.*, 2023, **14**, 75.
- R. Pattipeiluhu, G. Arias-Alpizar, G. Basha, K. Y. Chan, J. Bussmann, T. H. Sharp, M. A. Moradi, N. Sommerdijk, E. N. Harris and P. R. Cullis, *Adv. Mater.*, 2022, **34**, 2201095.
- N. Dammes, M. Goldsmith, S. Ramishetti, J. L. Dearling, N. Veiga, A. B. Packard and D. Peer, *Nat. Nanotechnol.*, 2021, **16**, 1030–1038.
- S. K. Patel, M. M. Billingsley, C. Frazee, X. Han, K. L. Swingle, J. Qin, M.-G. Alameh, K. Wang, D. Weissman and M. J. Mitchell, *J. Controlled Release*, 2022, **347**, 521–532.
- Y. Li, T. Ji, M. Torre, R. Shao, Y. Zheng, D. Wang, X. Li, A. Liu, W. Zhang, X. Deng, R. Yan and D. S. Kohane, *Nat. Commun.*, 2023, **14**, 6659.
- B. S. Pattni, V. V. Chupin and V. P. Torchilin, *Chem. Rev.*, 2015, **115**, 10938–10966.
- K. Paunovska, D. Loughrey and J. E. Dahlman, *Nat. Rev. Genet.*, 2022, **23**, 265–280.
- T. M. Allen and P. R. Cullis, *Science*, 2004, **303**, 1818–1822.
- S. Senapati, A. K. Mahanta, S. Kumar and P. Maiti, *Signal Transduction Targeted Ther.*, 2018, **3**, 7.
- A. Jesorka and O. Orwar, *Annu. Rev. Anal. Chem.*, 2008, **1**, 801–832.
- N. Filipczak, J. Pan, S. S. K. Yalamarty and V. P. Torchilin, *Adv. Drug Delivery Rev.*, 2020, **156**, 4–22.
- J. C. Kaczmarek, P. S. Kowalski and D. G. Anderson, *Genome Med.*, 2017, **9**, 60.
- R. van der Meel, E. Sulheim, Y. Shi, F. Kiessling, W. J. M. Mulder and T. Lammers, *Nat. Nanotechnol.*, 2019, **14**, 1007–1017.
- H. Xing, K. Hwang and Y. Lu, *Theranostics*, 2016, **6**, 1336–1352.
- R. H. Fang, W. Gao and L. Zhang, *Nat. Rev. Clin. Oncol.*, 2023, **20**, 33–48.
- J. A. Kulkarni, M. M. Darjuan, J. E. Mercer, S. Chen, R. van der Meel, J. L. Thewalt, Y. Y. C. Tam and P. R. Cullis, *ACS Nano*, 2018, **12**, 4787–4795.
- M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas and R. Langer, *Nat. Rev. Drug Discovery*, 2021, **20**, 101–124.
- D. Adams, A. Gonzalez-Duarte, W. D. O’Riordan, C. C. Yang, M. Ueda, A. V. Kristen, I. Tournev, H. H. Schmidt, T. Coelho, J. L. Berk, K. P. Lin, G. Vita, S. Attarian, V. Plante-Bordeneuve, M. M. Mezei, J. M. Campistol, J. Buades, T. H. Brannagan, III, B. J. Kim, J. Oh, Y. Parman, Y. Sekijima, P. N. Hawkins, S. D. Solomon, M. Polydefkis, P. J. Dyck, P. J. Gandhi, S. Goyal, J. Chen, A. L. Strahs, S. V. Nochur, M. T. Sweetser, P. P. Garg, A. K. Vaishnav, J. A. Gollob and O. B. Suhr, *N. Engl. J. Med.*, 2018, **379**, 11–21.
- U. Lächelt and E. Wagner, *Chem. Rev.*, 2015, **115**, 11043–11078.
- Y. Wang, S. Li, X. Wang, Q. Chen, Z. He, C. Luo and J. Sun, *Biomaterials*, 2021, **271**, 120737.
- M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas and R. Langer, *Nat. Rev. Drug Discovery*, 2021, **20**, 101–124.
- G. Yamankurt, E. J. Berns, A. Xue, A. Lee, N. Bagheri, M. Mrksich and C. A. Mirkin, *Nat. Biomed. Eng.*, 2019, **3**, 318–327.
- W. Jiang, C. A. von Roemeling, Y. Chen, Y. Qie, X. Liu, J. Chen and B. Y. S. Kim, *Nat. Biomed. Eng.*, 2017, **1**, 0029.
- M. J. W. Evers, J. A. Kulkarni, R. van der Meel, P. R. Cullis, P. Vader and R. M. Schiffelers, *Small Methods*, 2018, **2**(9), 1700375.
- M. Cobb, *Curr. Biol.*, 2015, **25**, R526–532.
- N. Veiga, M. Goldsmith, Y. Granot, D. Rosenblum, N. Dammes, R. Kedmi, S. Ramishetti and D. Peer, *Nat. Commun.*, 2018, **9**, 4493.
- G. Zhang, T. Tang, Y. Chen, X. Huang and T. Liang, *Signal Transduction Targeted Ther.*, 2023, **8**, 365.
- W. Ho, M. Gao, F. Li, Z. Li, X. Q. Zhang and X. Xu, *Adv. Healthcare Mater.*, 2021, **10**, e2001812.



- 29 Z. He, Y. Hu, T. Nie, H. Tang, J. Zhu, K. Chen, L. Liu, K. W. Leong, Y. Chen and H.-Q. Mao, *Acta Biomater.*, 2018, **81**, 195–207.
- 30 S. G. Jadhav and S. F. Dowdy, *Nat. Mater.*, 2021, **20**, 575–577.
- 31 R. Kole, A. R. Krainer and S. Altman, *Nat. Rev. Drug Discovery*, 2012, **11**, 125–140.
- 32 E. Samaridou, J. Heyes and P. Lutwyche, *Adv. Drug Delivery Rev.*, 2020, **154**, 37–63.
- 33 P. R. Cullis and M. J. Hope, *Mol. Ther.*, 2017, **25**, 1467–1475.
- 34 C. Hald Albertsen, J. A. Kulkarni, D. Witzigmann, M. Lind, K. Petersson and J. B. Simonsen, *Adv. Drug Delivery Rev.*, 2022, **188**, 114416.
- 35 J. A. Kulkarni, P. R. Cullis and R. Van Der Meel, *Nucleic Acid Ther.*, 2018, **28**, 146–157.
- 36 J. A. Kulkarni, D. Witzigmann, S. Chen, P. R. Cullis and R. van der Meel, *Acc. Chem. Res.*, 2019, **52**, 2435–2444.
- 37 C. H. Albertsen, J. A. Kulkarni, D. Witzigmann, M. Lind, K. Petersson and J. B. Simonsen, *Adv. Drug Delivery Rev.*, 2022, **188**, 114416.
- 38 J. D. Watson and F. H. C. Crick, *Nature*, 1953, **171**, 737–738.
- 39 W. H. Hudson and E. A. Ortlund, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 749–760.
- 40 I. Lostalé-Sejjo and J. Montenegro, *Nat. Rev. Chem.*, 2018, **2**, 258–277.
- 41 P. J. C. Lin, Y. Y. C. Tam, I. Hafez, A. Sandhu, S. Chen, M. A. Ciufolini, I. R. Nabi and P. R. Cullis, *Nanomedicine*, 2013, **9**, 233–246.
- 42 G. Basha, T. I. Novobrantseva, N. Rosin, Y. Y. Tam, I. M. Hafez, M. K. Wong, T. Sugo, V. M. Ruda, J. Qin, B. Klebanov, M. Ciufolini, A. Akinc, Y. K. Tam, M. J. Hope and P. R. Cullis, *Mol. Ther.*, 2011, **19**, 2186–2200.
- 43 H. Lv, S. Zhang, B. Wang, S. Cui and J. Yan, *J. Controlled Release*, 2006, **114**, 100–109.
- 44 Y. Sato, K. Hashiba, K. Sasaki, M. Maeki, M. Tokeshi and H. Harashima, *J. Controlled Release*, 2019, **295**, 140–152.
- 45 R. L. Ball, P. Bajaj and K. A. Whitehead, *Int. J. Nanomed.*, 2016, **12**, 305–315.
- 46 V. Kumar, J. Qin, Y. Jiang, R. G. Duncan, B. Brigham, S. Fishman, J. K. Nair, A. Akinc, S. A. Barros and P. V. Kasperkovitz, *Mol. Ther.–Nucleic Acids*, 2014, **3**, e210.
- 47 A. L. Bailey and P. R. Cullis, *Biochemistry*, 1997, **36**, 1628–1634.
- 48 M. Jayaraman, S. M. Ansell, B. L. Mui, Y. K. Tam, J. Chen, X. Du, D. Butler, L. Eltepu, S. Matsuda and J. K. Narayanannair, *Angew. Chem., Int. Ed.*, 2012, **124**, 8657–8661.
- 49 X. Han, H. Zhang, K. Butowska, K. L. Swingle, M.-G. Alameh, D. Weissman and M. J. Mitchell, *Nat. Commun.*, 2021, **12**, 7233.
- 50 J. Lutz, S. Lazzaro, M. Habbeldine, K. E. Schmidt, P. Baumhof, B. L. Mui, Y. K. Tam, T. D. Madden, M. J. Hope, R. Heidenreich and M. Fotin-Mleczek, *npj Vaccines*, 2017, **2**, 29.
- 51 F. Ferraresso, A. W. Strilchuk, L. J. Juang, L. G. Poole, J. P. Luyendyk and C. J. Kastrup, *Mol. Pharmaceutics*, 2022, **19**, 2175–2182.
- 52 X. Yu, S. Liu, Q. Cheng, T. Wei, S. Lee, D. Zhang and D. J. Siegwart, *Adv. Healthcare Mater.*, 2020, **9**, 1901487.
- 53 S. C. Semple, A. Akinc, J. Chen, A. P. Sandhu, B. L. Mui, C. K. Cho, D. W. Sah, D. Stebbing, E. J. Crosley and E. Yaworski, *Nat. Biotechnol.*, 2010, **28**, 172–176.
- 54 X. Cheng and R. J. Lee, *Adv. Drug Delivery Rev.*, 2016, **99**, 129–137.
- 55 D. Bochicchio, E. Panizon, L. Monticelli and G. Rossi, *Sci. Rep.*, 2017, **7**, 6357.
- 56 E. Ambegia, S. Ansell, P. Cullis, J. Heyes, L. Palmer and I. MacLachlan, *Biochim. Biophys. Acta, Biomembr.*, 2005, **1669**, 155–163.
- 57 P. Tam, M. Monck, D. Lee, O. Ludkovski, E. Leng, K. Clow, H. Stark, P. Scherrer, R. Graham and P. Cullis, *Gene Ther.*, 2000, **7**, 1867–1874.
- 58 T. Suzuki, Y. Suzuki, T. Hihara, K. Kubara, K. Kondo, K. Hyodo, K. Yamazaki, T. Ishida and H. Ishihara, *Int. J. Pharm.*, 2020, **588**, 119792.
- 59 H. Zhang, J. Leal, M. R. Soto, H. D. Smyth and D. Ghosh, *Pharmaceutics*, 2020, **12**, 1042.
- 60 S. G. Reed, M. T. Orr and C. B. Fox, *Nat. Med.*, 2013, **19**, 1597–1608.
- 61 M. T. M. García, Á. T. Lana, M. B. A. Agudo and M. T. R. Delgado, *Enferm. Infecc. Microbiol. Clin.*, 2022, **40**, 276.
- 62 M. Tamburro, G. Ripabelli, A. D'Amico, R. De Dona, M. Iaffigliola, A. Parente, N. Samprati, A. Santagata, C. Adesso, A. Natale, M. A. Di Palma, F. Cannizzaro and M. L. Sammarco, *J. Community Health*, 2022, **47**, 814–821.
- 63 M. P. Lokugamage, D. Vanover, J. Beyersdorf, M. Z. Hatit, L. Rotolo, E. S. Echeverri, H. E. Peck, H. Ni, J.-K. Yoon and Y. Kim, *Nat. Biomed. Eng.*, 2021, **5**, 1059–1068.
- 64 X. Cheng and R. J. Lee, *Adv. Drug Delivery Rev.*, 2016, **99**, 129–137.
- 65 X. Cheng and R. J. Lee, *Adv. Drug Delivery Rev.*, 2016, **99**, 129–137.
- 66 J. A. Kulkarni, J. L. Myhre, S. Chen, Y. Y. C. Tam, A. Danescu, J. M. Richman and P. R. Cullis, *Nanomedicine*, 2017, **13**, 1377–1387.
- 67 Y. Zhu, R. Shen, I. Vuong, R. A. Reynolds, M. J. Shears, Z.-C. Yao, Y. Hu, W. J. Cho, J. Kong and S. K. Reddy, *Nat. Commun.*, 2022, **13**, 4282.
- 68 S. T. LoPresti, M. L. Arral, N. Chaudhary and K. A. Whitehead, *J. Controlled Release*, 2022, **345**, 819–831.
- 69 R. Zhang, R. El-Mayta, T. J. Murdoch, C. C. Warzecha, M. M. Billingsley, S. J. Shepherd, N. Gong, L. Wang, J. M. Wilson and D. Lee, *Biomater. Sci.*, 2021, **9**, 1449–1463.
- 70 E. Álvarez-Benedicto, L. Farbiak, M. M. Ramírez, X. Wang, L. T. Johnson, O. Mian, E. D. Guerrero and D. J. Siegwart, *Biomater. Sci.*, 2022, **10**, 549–559.
- 71 T. Harayama and H. Riezman, *Nat. Rev. Mol. Cell Biol.*, 2018, **19**, 281–296.
- 72 M. R. Krause and S. L. Regen, *Acc. Chem. Res.*, 2014, **47**, 3512–3521.
- 73 X. Xie, T. Yu, X. Li, N. Zhang, L. J. Foster, C. Peng, W. Huang and G. He, *Signal Transduction Targeted Ther.*, 2023, **8**, 335.
- 74 S. T. Crooke, J. L. Witztum, C. F. Bennett and B. F. Baker, *Cell Metab.*, 2018, **27**, 714–739.



- 75 Z. Dominski and R. Kole, *Proc. Natl. Acad. Sci. U. S. A.*, 1993, **90**, 8673–8677.
- 76 P. D. Zamore, T. Tuschl, P. A. Sharp and D. P. Bartel, *Cell*, 2000, **101**, 25–33.
- 77 S. M. Hammond, E. Bernstein, D. Beach and G. J. Hannon, *Nature*, 2000, **404**, 293–296.
- 78 S. Mitschka and C. Mayr, *Nat. Rev. Mol. Cell Biol.*, 2022, **23**, 779–796.
- 79 H. Maeda, J. Wu, T. Sawa, Y. Matsumura and K. Hori, *J. Controlled Release*, 2000, **65**, 271–284.
- 80 H. Maeda, J. Wu, T. Sawa, Y. Matsumura and K. Hori, *J. Controlled Release*, 2000, **65**, 271–284.
- 81 F. Heymann and F. Tacke, *Nat. Rev. Gastroenterol. Hepatol.*, 2016, **13**, 88–110.
- 82 M. W. Robinson, C. Harmon and C. O'Farrelly, *Cell. Mol. Immunol.*, 2016, **13**, 267–276.
- 83 E. Trefts, M. Gannon and D. H. Wasserman, *Curr. Biol.*, 2017, **27**, R1147–r1151.
- 84 P. Kuberski and C. Jenne, *Annu. Rev. Immunol.*, 2018, **36**, 247–277.
- 85 R. Böttger, G. Pauli, P.-H. Chao, N. A. Fayed, L. Hohenwarter and S.-D. Li, *Adv. Drug Delivery Rev.*, 2020, **154**, 79–101.
- 86 P. Thomas, in *Encyclopedia of Cancer*, ed. M. Schwab, Springer Berlin Heidelberg, Berlin, Heidelberg, 2011, pp.1963–1965.
- 87 M. Bilzer, F. Roggel and A. L. Gerbes, *Liver Int.*, 2006, **26**, 1175–1186.
- 88 S. N. Hilmer, V. C. Cogger and D. G. Le Couteur, *J. Gerontol., Ser. A*, 2007, **62**, 973–978.
- 89 G. Kolios, V. Valatas and E. Kouroumalis, *World J. Gastroenterol.*, 2006, **12**, 7413–7420.
- 90 H. Ruf and B. J. Gould, *Eur. Biophys. J.*, 1999, **28**, 1–11.
- 91 D. Bente, A. Follenzi, K. K. Bhargava, V. Kumaran, C. J. Palestro and S. Gupta, *Hepatology*, 2005, **42**, 140–148.
- 92 A. Geerts, *Semin. Liver Dis.*, 2001, **21**, 311–335.
- 93 F. Winau, G. Hegasy, R. Weiskirchen, S. Weber, C. Cassan, P. A. Sieling, R. L. Modlin, R. S. Liblau, A. M. Gressner and S. H. Kaufmann, *Immunity*, 2007, **26**, 117–129.
- 94 S. L. Friedman, *Physiol. Rev.*, 2008, **88**, 125–172.
- 95 S. R. Wang, G. Renaud, J. Infante, D. Catala and R. Infante, *In Vitro Cell. Dev. Biol.*, 1985, **21**, 526–530.
- 96 S. Donthamsetty, V. S. Bhave, C. S. Kliment, W. C. Bowen, W. M. Mars, A. W. Bell, R. E. Stewart, A. Orr, C. Wu and G. K. Michalopoulos, *Hepatology*, 2011, **53**, 587–595.
- 97 S. Novakowski, K. Jiang, G. Prakash and C. Kastrup, *Sci. Rep.*, 2019, **9**, 552.
- 98 T. Kanazawa, K. Morisaki, S. Suzuki and Y. Takashima, *Mol. Pharmaceutics*, 2014, **11**, 1471–1478.
- 99 J. K. Lam, W. Liang and H. K. Chan, *Adv. Drug Delivery Rev.*, 2012, **64**, 1–15.
- 100 E. Blanco, H. Shen and M. Ferrari, *Nat. Biotechnol.*, 2015, **33**, 941–951.
- 101 D. Lechardeur, K. J. Sohn, M. Haardt, P. B. Joshi, M. Monck, R. W. Graham, B. Beatty, J. Squire, H. O'Brodovich and G. L. Lukacs, *Gene Ther.*, 1999, **6**, 482–497.
- 102 S. Liu, Q. Cheng, T. Wei, X. Yu, L. T. Johnson, L. Farbiak and D. J. Siegwart, *Nat. Mater.*, 2021, **20**, 701–710.
- 103 J. Szebeni, G. Storm, J. Y. Ljubimova, M. Castells, E. J. Phillips, K. Turjeman, Y. Barenholz, D. J. A. Crommelin and M. A. Dobrovolskaia, *Nat. Nanotechnol.*, 2022, **17**, 337–346.
- 104 E. L. Romero, M. J. Morilla, J. Regts, G. A. Koning and G. L. Scherphof, *FEBS Lett.*, 1999, **448**, 193–196.
- 105 A. Wieckowska, A. J. McCullough and A. E. Feldstein, *Hepatology*, 2007, **46**, 582–589.
- 106 V. Thakur, M. R. McMullen, M. T. Pritchard and L. E. Nagy, *J. Gastroenterol. Hepatol.*, 2007, **22**(Suppl 1), S53–S56.
- 107 S. L. Friedman and M. B. Bansal, *Hepatology*, 2006, **43**, S82–88.
- 108 H. Robertson, J. A. Kirby, W. W. Yip, D. E. Jones and A. D. Burt, *Hepatology*, 2007, **45**, 977–981.
- 109 I. Fabregat, C. Roncero and M. Fernández, *Liver Int.*, 2007, **27**, 155–162.
- 110 S. Taurin, H. Nehoff and K. Greish, *J. Controlled Release*, 2012, **164**, 265–275.
- 111 M. Qiu, Y. Tang, J. Chen, R. Muriph, Z. Ye, C. Huang, J. Evans, E. P. Henske and Q. Xu, *Proc. Natl. Acad. Sci. U. S. A.*, 2022, **119**(8), e2116271119.
- 112 M. Kockx, M. Traini and L. Kritharides, *J. Mol. Med.*, 2018, **96**, 361–371.
- 113 K. Paunovska, A. J. Da Silva Sanchez, M. P. Lokugamage, D. Loughrey, E. S. Echeverri, A. Cristian, M. Z. C. Hatit, P. J. Santangelo, K. Zhao and J. E. Dahlman, *Nano Lett.*, 2022, **22**, 10025–10033.
- 114 A. Akinc, W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, K. N. Jayaprakash, M. Jayaraman, K. G. Rajeev, W. L. Cantley and J. R. Dorkin, *Mol. Ther.*, 2010, **18**, 1357–1364.
- 115 F. Sebastiani, M. Yanez Arteta, M. Lerche, L. Porcar, C. Lang, R. A. Bragg, C. S. Elmore, V. R. Krishnamurthy, R. A. Russell, T. Darwish, H. Pichler, S. Waldie, M. Moulin, M. Haertlein, V. T. Forsyth, L. Lindfors and M. Cárdenas, *ACS Nano*, 2021, **15**, 6709–6722.
- 116 M. Kim, M. Jeong, S. Hur, Y. Cho, J. Park, H. Jung, Y. Seo, H. Woo, K. Nam and K. Lee, *Sci. Adv.*, 2021, **7**, eabf4398.
- 117 J. E. Zhou, L. Sun, L. Liu, Y. Jia, Y. Han, J. Shao, J. Wang, Y. Wang, L. Yu and Z. Yan, *J. Controlled Release*, 2022, **343**, 175–186.
- 118 J. Zhang, H. Shen, J. Xu, L. Liu, J. Tan, M. Li, N. Xu, S. Luo, J. Wang, F. Yang, J. Tang, Q. Li, Y. Wang, L. Yu and Z. Yan, *ACS Nano*, 2020, **14**, 6305–6322.
- 119 H. Ni, M. Z. C. Hatit, K. Zhao, D. Loughrey, M. P. Lokugamage, H. E. Peck, A. D. Cid, A. Muralidharan, Y. Kim, P. J. Santangelo and J. E. Dahlman, *Nat. Commun.*, 2022, **13**, 4766.
- 120 Z. Yang, Y. Liu, K. Zhao, W. Jing, L. Gao, X. Dong, Y. Wang, M. Han, C. Shi, C. Tang, P. Sun, R. Zhang, Z. Fu, J. Zhang, D. Zhu, C. Chen and X. Jiang, *J. Controlled Release*, 2023, **360**, 718–733.
- 121 M. Qiu, Z. Glass, J. Chen, M. Haas, X. Jin, X. Zhao, X. Rui, Z. Ye, Y. Li, F. Zhang and Q. Xu, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**(10), e2020401118.



- 122 M. C. S. Wong, J. L. W. Huang, J. George, J. Huang, C. Leung, M. Eslam, H. L. Y. Chan and S. C. Ng, *Nat. Rev. Gastroenterol. Hepatol.*, 2019, **16**, 57–73.
- 123 J. D. Stanaway, A. D. Flaxman, M. Naghavi, C. Fitzmaurice, T. Vos, I. Abubakar, L. J. Abu-Raddad, R. Assadi, N. Bhala, B. Cowie, M. H. Forouzanfour, J. Groeger, K. M. Hanafiah, K. H. Jacobsen, S. L. James, J. MacLachlan, R. Malekzadeh, N. K. Martin, A. A. Mokdad, A. H. Mokdad, C. J. L. Murray, D. Plass, S. Rana, D. B. Rein, J. H. Richardus, J. Sanabria, M. Saylan, S. Shahraz, S. So, V. V. Vlassov, E. Weiderpass, S. T. Wiersma, M. Younis, C. Yu, M. El Sayed Zaki and G. S. Cooke, *Lancet*, 2016, **388**, 1081–1088.
- 124 S. K. Asrani, H. Devarbhavi, J. Eaton and P. S. Kamath, *J. Hepatol.*, 2019, **70**, 151–171.
- 125 Z. Younossi, Q. M. Anstee, M. Marietti, T. Hardy, L. Henry, M. Eslam, J. George and E. Bugianesi, *Nat. Rev. Gastroenterol. Hepatol.*, 2018, **15**, 11–20.
- 126 M. A. Aldersley and J. G. O'Grady, *Drugs*, 1995, **49**, 83–102.
- 127 V. Hernandez-Gea and S. L. Friedman, *Annu. Rev. Phytopathol.*, 2011, **6**, 425–456.
- 128 Z. M. Younossi, *J. Hepatol.*, 2019, **70**, 531–544.
- 129 J. S. Bajaj, *Nat. Rev. Gastroenterol. Hepatol.*, 2019, **16**, 235–246.
- 130 R. Böttger, G. Pauli, P.-H. Chao, N. Al Fayed, L. Hohenwarter and S.-D. Li, *Adv. Drug Delivery Rev.*, 2020, **154–155**, 79–101.
- 131 D. Witzigmann, J. A. Kulkarni, J. Leung, S. Chen, P. R. Cullis and R. van der Meel, *Adv. Drug Delivery Rev.*, 2020, **159**, 344–363.
- 132 J. Hu, Y. Xu, J. Hao, S. Wang, C. Li and S. Meng, *Protein Cell*, 2012, **3**, 364–371.
- 133 N. Gonzaludo, J. W. Belmont, V. G. Gainullin and R. J. Taft, *Genet. Med.*, 2019, **21**, 1781–1789.
- 134 J. Menon, M. Vij, D. Sachan, A. Rammohan, N. Shanmugam, I. Kaliamoorthy and M. Rela, *World J. Transplant.*, 2021, **11**, 161.
- 135 R. Hegarty, N. Hadzic, P. Gissen and A. Dhawan, *Eur. J. Pediatr.*, 2015, **174**, 1387–1392.
- 136 C. R. Ferreira, D. Cassiman and N. Blau, *Mol. Genet. Metab.*, 2019, **127**, 117–121.
- 137 J. S. Kim, K. M. Kim, S. H. Oh, H. J. Kim, J. M. Cho, H.-W. Yoo, J.-M. Namgoong, D. Y. Kim, K.-H. Kim and S. Hwang, *Pediatr. Gastroenterol. Hepatol. Nutr.*, 2015, **18**, 48–54.
- 138 A. Zarrinpar and R. W. Busuttil, *Nat. Rev. Gastroenterol. Hepatol.*, 2013, **10**, 434–440.
- 139 Y. Granot and D. Peer, *Semin. Immunol.*, 2017, **34**, 68–77.
- 140 B. Carroll, V. I. Korolchuk and S. Sarkar, *Amino Acids*, 2015, **47**, 2065–2088.
- 141 J. Jung, H. Zeng and T. Horng, *Nat. Cell Biol.*, 2019, **21**, 85–93.
- 142 P. Strzycz, *Nat. Rev. Mol. Cell Biol.*, 2015, **16**, 703.
- 143 Z. Dai, Z. Wu, W. Zhu and G. Wu, in *Recent Advances in Animal Nutrition and Metabolism*, ed. G. Wu, Springer International Publishing, Cham, 2022, pp.127–143.
- 144 D. Gyamfi and K. O. Danquah, in *Molecular Aspects of Alcohol and Nutrition*, ed. V. B. Patel, Academic Press, San Diego, 2016, pp.3–15.
- 145 A. Dursun, R. K. Özgül, S. Sivri, A. Tokath, A. Güzel, L. Mesci, M. Kiliç, D. Aliefendioğlu, F. Özçay, M. Gündüz and T. Coşkun, *JIMD Reports - Case and Research Reports, 2011/1: Case and Research Reports*, Springer Berlin Heidelberg, Berlin, Heidelberg, 2011, pp.17–21.
- 146 Q. Cheng, T. Wei, Y. Jia, L. Farbiak, K. Zhou, S. Zhang, Y. Wei, H. Zhu and D. J. Siegwart, *Adv. Mater.*, 2018, **30**, 1805308.
- 147 M. L. Cacicedo, C. Weinel-Tenbruck, D. Frank, S. Wirsching, B. K. Straub, J. Hauke, J. G. Okun, N. Horscroft, J. B. Hennermann and F. Zepp, *Mol. Ther.–Methods Clin. Dev.*, 2022, **26**, 294–308.
- 148 M. L. Cacicedo, C. Weinel-Tenbruck, D. Frank, M. J. Limeres, S. Wirsching, K. Hilbert, M. A. Pasha Famian, N. Horscroft, J. B. Hennermann and F. Zepp, *Front. Bioeng. Biotechnol.*, 2022, **10**, 993298.
- 149 B. Truong, G. Allegri, X.-B. Liu, K. E. Burke, X. Zhu, S. D. Cederbaum, J. Häberle, P. G. Martini and G. S. Lipshutz, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 21150–21159.
- 150 K. Tanaka, in *Biology of Brain Dysfunction*, ed. G. E. Gaull, Springer, US, Boston, MA, 1975, vol. 3, pp.145–214.
- 151 M. R. Seashore, in *Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease*, ed. R. N. Rosenberg and J. M. Pascual, Academic Press, Boston, 5th edn, 2015, pp.601–606.
- 152 L. Jiang, J.-S. Park, L. Yin, R. Laureano, E. Jacquinet, J. Yang, S. Liang, A. Frassetto, J. Zhuo and X. Yan, *Nat. Commun.*, 2020, **11**, 5339.
- 153 D. An, A. Frassetto, E. Jacquinet, M. Eybye, J. Milano, C. DeAntonis, V. Nguyen, R. Laureano, J. Milton and S. Sabnis, *EBioMedicine*, 2019, **45**, 519–528.
- 154 P. S. Kishnani, J. Goldstein, S. L. Austin, P. Arn, B. Bachrach, D. S. Bali, W. K. Chung, A. El-Gharbawy, L. M. Brown, S. Kahler, S. Pendyal, K. M. Ross, L. Tsilianidis, D. A. Weinstein, M. S. Watson and ACMG Work Group on Diagnosis and Management of Glycogen Storage Diseases Type VI and IX, *Genet. Med.*, 2019, **21**, 772–789.
- 155 W. B. Hannah, T. G. J. Derks, M. L. Drumm, S. C. Grünert, P. S. Kishnani and J. Vissing, *Nat. Rev. Dis. Primers*, 2023, **9**, 46.
- 156 J. Cao, M. Choi, E. Guadagnin, M. Soty, M. Silva, V. Verzieux, E. Weisser, A. Markel, J. Zhuo, S. Liang, L. Yin, A. Frassetto, A. R. Graham, K. Burke, T. Ketova, C. Mihai, Z. Zalinger, B. Levy, G. Besin, M. Wolfrom, B. Tran, C. Tunkey, E. Owen, J. Sarkis, A. Dousis, V. Presnyak, C. Pepin, W. Zheng, L. Ci, M. Hard, E. Miracco, L. Rice, V. Nguyen, M. Zimmer, U. Rajarajacholan, P. F. Finn, G. Mithieux, F. Rajas, P. G. V. Martini and P. H. Giangrande, *Nat. Commun.*, 2021, **12**, 3090.
- 157 S. Fagioli, E. Daina, L. D'Antiga, M. Colledan and G. Remuzzi, *J. Hepatol.*, 2013, **59**, 595–612.
- 158 J. A. Greig, J. K. Chorazeczewski, V. Chowdhary, M. K. Smith, M. Jennis, J. C. Tarrant, E. L. Buza, K. Coughlan, P. G. Martini and J. M. Wilson, *Mol. Ther.–Methods Clin. Dev.*, 2023, **29**, 32–39.



- 159 G. Wei, J. Cao, P. Huang, P. An, D. Badlani, K. A. Vaid, S. Zhao, D. Q. Wang, J. Zhuo and L. Yin, *J. Hepatol.*, 2021, **74**, 1416–1428.
- 160 E. C. Lo, A. N. Rucker and M. P. Federle, *Semin. Radiat. Oncol.*, 2018, **28**, 267–276.
- 161 P. A. Ott, F. S. Hodi, H. L. Kaufman, J. M. Wigginton and J. D. Wolchok, *J. Immunotherap. Cancer.*, 2017, **5**, 16.
- 162 B. Sangro, P. Sarobe, S. Hervás-Stubbs and I. Melero, *Nat. Rev. Gastroenterol. Hepatol.*, 2021, **18**, 525–543.
- 163 S. Yang, D. Wang, X. Zhang, Y. Sun and B. Zheng, *Drug Delivery*, 2021, **28**, 995–1006.
- 164 L. Yuhuan, Y. Kongtong, B. Ye, Q. Yuhang, S. Yating, L. Yujing, X. Jing and T. Lesheng, *ACS Appl. Mater. Interfaces*, 2016, **8**, 26613–26621.
- 165 B. Yu, S.-H. Hsu, C. Zhou, X. Wang, M. C. Terp, Y. Wu, L. Teng, Y. Mao, F. Wang and W. Xue, *Biomaterials*, 2012, **33**, 5924–5934.
- 166 M. M. Voitok, M. E. Zoubek, D. Doleschel, M. Bartneck, M. R. Mohamed, F. Kießling, W. Lederle, C. Trautwein and F. J. Cubero, *Cell Death Dis.*, 2020, **11**, 343.
- 167 M. A. Younis, I. A. Khalil, Y. H. Elewa, Y. Kon and H. Harashima, *J. Controlled Release*, 2021, **331**, 335–349.
- 168 Y. Rybakova, P. S. Kowalski, Y. Huang, J. T. Gonzalez, M. W. Heartlein, F. DeRosa, D. Delcassian and D. G. Anderson, *Mol. Ther.*, 2019, **27**, 1415–1423.
- 169 Z. Wang, K. Zhao, Y. Zhang, X. Duan and Y. Zhao, *Pharm. Res.*, 2019, **36**, 1–13.
- 170 I. Lai, S. Swaminathan, V. Baylot, A. Mosley, R. Dhanasekaran, M. Gabay and D. W. Felsher, *J. Immunotherap. Cancer.*, 2018, **6**, 1–11.
- 171 Y. Wang, K. Tiruthani, S. Li, M. Hu, G. Zhong, Y. Tang, S. Roy, L. Zhang, J. Tan and C. Liao, *Adv. Mater.*, 2021, **33**, 2007603.
- 172 D. Zhang, G. Wang, X. Yu, T. Wei, L. Farbiak, L. T. Johnson, A. M. Taylor, J. Xu, Y. Hong and H. Zhu, *Nat. Nanotechnol.*, 2022, **17**, 777–787.
- 173 S.-h Hsu, B. Yu, X. Wang, Y. Lu, C. R. Schmidt, R. J. Lee, L. J. Lee, S. T. Jacob and K. Ghoshal, *Nanomedicine*, 2013, **9**, 1169–1180.
- 174 X. Wang, B. Yu, W. Ren, X. Mo, C. Zhou, H. He, H. Jia, L. Wang, S. T. Jacob and R. J. Lee, *J. Controlled Release*, 2013, **172**, 690–698.
- 175 Y.-S. Lim and W. R. Kim, *Clin. Liver Dis.*, 2008, **12**, 733–746.
- 176 T. A. Wynn and T. R. Ramalingam, *Nat. Med.*, 2012, **18**, 1028–1040.
- 177 C. Bonnans, J. Chou and Z. Werb, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 786–801.
- 178 T. Tsuchida and S. L. Friedman, *Nat. Rev. Gastroenterol. Hepatol.*, 2017, **14**, 397–411.
- 179 T. Kisseleva and D. Brenner, *Nat. Rev. Gastroenterol. Hepatol.*, 2021, **18**, 151–166.
- 180 J. Zhang, H. Shen, J. Xu, L. Liu, J. Tan, M. Li, N. Xu, S. Luo, J. Wang and F. Yang, *ACS Nano*, 2020, **14**, 6305–6322.
- 181 Z. Jia, Y. Gong, Y. Pi, X. Liu, L. Gao, L. Kang, J. Wang, F. Yang, J. Tang and W. Lu, *Mol. Pharmaceutics*, 2018, **15**, 53–62.
- 182 E. J. Lawitz, D. E. Shevell, G. S. Tirucherai, S. Du, W. Chen, U. Kavita, A. Coste, F. Poordad, M. Karsdal and M. Nielsen, *Hepatology*, 2022, **75**, 912–923.
- 183 C. Jiménez Calvente, A. Sehgal, Y. Popov, Y. O. Kim, V. Zevallos, U. Sahin, M. Diken and D. Schuppan, *Hepatology*, 2015, **62**, 1285–1297.
- 184 J.-B. Qiao, Q.-Q. Fan, C.-L. Zhang, J. Lee, J. Byun, L. Xing, X.-D. Gao, Y.-K. Oh and H.-L. Jiang, *J. Controlled Release*, 2020, **321**, 629–640.
- 185 T. Yang, M. Poenisch, R. Khanal, Q. Hu, Z. Dai, R. Li, G. Song, Q. Yuan, Q. Yao and X. Shen, *J. Hepatol.*, 2021, **75**, 1420–1433.
- 186 M. Hu, Y. Wang, Z. Liu, Z. Yu, K. Guan, M. Liu, M. Wang, J. Tan and L. Huang, *Nat. Nanotechnol.*, 2021, **16**, 466–477.
- 187 S. Kathiresan, O. Melander, C. Guiducci, A. Surti, N. P. Burt, M. J. Rieder, G. M. Cooper, C. Roos, B. F. Voight, A. S. Havulinna, B. Wahlstrand, T. Hedner, D. Corella, E. S. Tai, J. M. Ordovas, G. Berglund, E. Vartiainen, P. Jousilahti, B. Hedblad, M.-R. Taskinen, C. Newton-Cheh, V. Salomaa, L. Peltonen, L. Groop, D. M. Altshuler and M. Orho-Melander, *Nat. Genet.*, 2008, **40**, 189–197.
- 188 Y.-Y. Zhang, Z.-Y. Fu, J. Wei, W. Qi, G. Baituola, J. Luo, Y.-J. Meng, S.-Y. Guo, H. Yin and S.-Y. Jiang, *Science*, 2018, **360**, 1087–1092.
- 189 B.-B. Chu, Y.-C. Liao, W. Qi, C. Xie, X. Du, J. Wang, H. Yang, H.-H. Miao, B.-L. Li and B.-L. Song, *Cell*, 2015, **161**, 291–306.
- 190 M. Qiu, Z. Glass, J. Chen, M. Haas, X. Jin, X. Zhao, X. Rui, Z. Ye, Y. Li and F. Zhang, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2020401118.
- 191 K. Musunuru, A. C. Chadwick, T. Mizoguchi, S. P. Garcia, J. E. DeNizio, C. W. Reiss, K. Wang, S. Iyer, C. Dutta and V. Clendaniel, *Nature*, 2021, **593**, 429–434.
- 192 Y. Suzuki, K. Hyodo, T. Suzuki, Y. Tanaka, H. Kikuchi and H. Ishihara, *Int. J. Pharm.*, 2017, **519**, 34–43.
- 193 L. Yang, F. Ma, F. Liu, J. Chen, X. Zhao and Q. Xu, *Mol. Ther. – Nucleic Acids*, 2020, **19**, 1357–1367.
- 194 M. Tadin-Strapps, L. B. Peterson, A.-M. Cumiskey, R. L. Rosa, V. H. Mendoza, J. Castro-Perez, O. Puig, L. Zhang, W. R. Strapps, S. Yendluri, L. Andrews, V. Pickering, J. Rice, L. Luo, Z. Chen, S. Tep, B. Ason, E. P. Somers, A. B. Sachs, S. R. Bartz, J. Tian, J. Chin, B. K. Hubbard, K. K. Wong and L. J. Mitnaul, *J. Lipid Res.*, 2011, **52**, 1084–1097.
- 195 D. Q. Huang, A. G. Singal, Y. Kono, D. J. H. Tan, H. B. El-Serag and R. Loomba, *Cell Metab.*, 2022, **34**, 969–977.
- 196 F. Rizvi, E. Everton, A. R. Smith, H. Liu, E. Osota, M. Beattie, Y. Tam, N. Pardi, D. Weissman and V. Gouon-Evans, *Nat. Commun.*, 2021, **12**, 613.
- 197 J.-E. Zhou, L. Sun, L. Liu, Y. Jia, Y. Han, J. Shao, J. Wang, Y. Wang, L. Yu and Z. Yan, *J. Controlled Release*, 2022, **343**, 175–186.
- 198 A. K. Soutar and R. P. Naoumova, *Nat. Clin. Pract. Cardiovasc. Med.*, 2007, **4**, 214–225.
- 199 G. Migliara, V. Baccolini, A. Rosso, E. D'Andrea, A. Massimi, P. Villari and C. De Vito, *Front Public Health*, 2017, **5**, 252.



- 200 L. N. Kasiewicz, S. Biswas, A. Beach, H. Ren, C. Dutta, A. M. Mazzola, E. Rohde, A. C. Chadwick, C. Cheng, K. Musunuru, S. Kathiresan, P. Malyala, K. G. Rajeev and A. M. Bellinger, *bioRxiv*, 2021.
- 201 M. R. McGill and H. Jaeschke, in *Studies on Hepatic Disorders*, ed. E. Albano and M. Parola, Springer International Publishing, Cham, 2015, pp.199–214.
- 202 V. Arroyo, R. Moreau, P. S. Kamath, R. Jalan, P. Ginès, F. Nevens, J. Fernández, U. To, G. García-Tsao and B. Schnabl, *Nat. Rev. Dis. Primers*, 2016, **2**, 16041.
- 203 W. Kawase, D. Kurotaki, Y. Suzuki, H. Ishihara, T. Ban, G. R. Sato, J. Ichikawa, H. Yanai, T. Taniguchi, K. Tsukahara and T. Tamura, *Mol. Ther.–Nucleic Acids*, 2021, **25**, 708–715.
- 204 Q. Yin, X. Song, P. Yang, W. Yang, X. Li, X. Wang and S. Wang, *Nanomedicine*, 2023, **48**, 102649.
- 205 Y. Sato, H. Matsui, N. Yamamoto, R. Sato, T. Munakata, M. Kohara and H. Harashima, *J. Controlled Release*, 2017, **266**, 216–225.
- 206 B. Chen, Y. Chen, J. Li, C. Wang, W. Song, Y. Wen, J. Lin, Y. Wu and T. Ying, *mBio*, 2022, **13**, e0161222.
- 207 N. M. Belliveau, J. Huft, P. J. C. Lin, S. Chen, A. K. K. Leung, T. J. Leaver, A. W. Wild, J. B. Lee, R. J. Taylor, Y. K. Tam, C. L. Hansen and P. R. Cullis, *Mol. Ther.–Nucleic Acids*, 2012, **1**, e37.
- 208 K. Batt, S. Xing, M. Kuharic, M. Bullano, J. Caicedo, S. Chakladar, R. Markan and S. Farahbakhshian, *Haemophilia*, 2023, **29**, 809–818.
- 209 J. P. Han, M. Kim, B. S. Choi, J. H. Lee, G. S. Lee, M. Jeong, Y. Lee, E.-A. Kim, H.-K. Oh and N. Go, *Sci. Adv.*, 2022, **8**, eabj6901.
- 210 F. DeRosa, B. Guild, S. Karve, L. Smith, K. Love, J. R. Dorkin, K. J. Kauffman, J. Zhang, B. Yahalom, D. G. Anderson and M. W. Heartlein, *Gene Ther.*, 2016, **23**, 699–707.
- 211 C.-Y. Chen, D. M. Tran, A. Cavedon, X. Cai, R. Rajendran, M. J. Lyle, P. G. V. Martini and C. H. Miao, *Mol. Ther.–Nucleic Acids*, 2020, **20**, 534–544.
- 212 Y. Sekijima, *J. Neurol., Neurosurg. Psychiatry*, 2015, **86**, 1036–1043.
- 213 M. S. Maurer, J. H. Schwartz, B. Gundapaneni, P. M. Elliott, G. Merlini, M. Waddington-Cruz, A. V. Kristen, M. Grogan, R. Witteles, T. Damy, B. M. Drachman, S. J. Shah, M. Hanna, D. P. Judge, A. I. Barsdorf, P. Huber, T. A. Patterson, S. Riley, J. Schumacher, M. Stewart, M. B. Sultan and C. Rapezzi, *N. Engl. J. Med.*, 2018, **379**, 1007–1016.
- 214 J. D. Finn, A. R. Smith, M. C. Patel, L. Shaw, M. R. Youniss, J. van Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. R. Shah, A. Shah, D. Ling, J. Growe, M. Pink, E. Rohde, K. M. Wood, W. E. Salomon, W. F. Harrington, C. Dombrowski, W. R. Strapps, Y. Chang and D. V. Morrissey, *Cell Rep.*, 2018, **22**, 2227–2235.
- 215 C. Niemietz, O. Nadzemova, A. Zibert and H. H. J. Schmidt, *Amyloid*, 2020, **27**, 45–51.
- 216 Y. Wei, L. Quan, C. Zhou and Q. Zhan, *Nanomedicine*, 2018, **13**, 1495–1512.
- 217 T. Nakamura, M. Kawai, Y. Sato, M. Maeki, M. Tokeshi and H. Harashima, *Mol. Pharmaceutics*, 2020, **17**, 944–953.
- 218 S. Chen, Y. Y. C. Tam, P. J. C. Lin, M. M. H. Sung, Y. K. Tam and P. R. Cullis, *J. Controlled Release*, 2016, **235**, 236–244.
- 219 P. H. Huang, S. Zhao, H. Bachman, N. Nama, Z. Li, C. Chen, S. Yang, M. Wu, S. P. Zhang and T. J. Huang, *Adv. Sci.*, 2019, **6**, 1900913.
- 220 N. Kimura, M. Maeki, Y. Sato, Y. Note, A. Ishida, H. Tani, H. Harashima and M. Tokeshi, *ACS Omega*, 2018, **3**, 5044–5051.
- 221 C. C. L. Cheung and W. T. Al-Jamal, *Int. J. Pharm.*, 2019, **566**, 687–696.
- 222 J. Y. Han, J. N. La Fiandra and D. L. DeVoe, *Nat. Commun.*, 2022, **13**, 6997.
- 223 J. M. Lim, A. Swami, L. M. Gilson, S. Chopra, S. Choi, J. Wu, R. Langer, R. Karnik and O. C. Farokhzad, *ACS Nano*, 2014, **8**, 6056–6065.
- 224 S. J. Shepherd, C. C. Warzecha, S. Yadavali, R. El-Mayta, M. G. Alameh, L. Wang, D. Weissman, J. M. Wilson, D. Issadore and M. J. Mitchell, *Nano Lett.*, 2021, **21**, 5671–5680.
- 225 N. M. Belliveau, J. Huft, P. J. Lin, S. Chen, A. K. Leung, T. J. Leaver, A. W. Wild, J. B. Lee, R. J. Taylor, Y. K. Tam, C. L. Hansen and P. R. Cullis, *Mol. Ther.–Nucleic Acids*, 2012, **1**, e37.
- 226 D. Desai, Y. A. Guerrero, V. Balachandran, A. Morton, L. Lyon, B. Larkin and D. E. Solomon, *Nanomedicine*, 2021, **35**, 102402.
- 227 M. J. Toth, T. Kim and Y. Kim, *Lab Chip*, 2017, **17**, 2805–2813.
- 228 K. S. Elvira, X. Casadevall i Solvas, R. C. Wootton and A. J. deMello, *Nat. Chem.*, 2013, **5**, 905–915.
- 229 Z. Ma, H. Tong, S. Lin, L. Zhou, D. Sun, B. Li, C. Tian and J. Chu, *Nano Res.*, 2024, **17**, 2899–2907.
- 230 E. Kon, U. Elia and D. Peer, *Curr. Opin. Biotechnol*, 2022, **73**, 329–336.
- 231 D. J. A. Crommelin, T. J. Anchordoquy, D. B. Volkin, W. Jiskoot and E. Mastrobattista, *J. Pharm. Sci.*, 2021, **110**, 997–1001.
- 232 R. L. Ball, P. Bajaj and K. A. Whitehead, *Int. J. Nanomed.*, 2017, **12**, 305–315.
- 233 M. Packer, D. Gyawali, R. Yerabolu, J. Schariter and P. White, *Nat. Commun.*, 2021, **12**, 6777.
- 234 S. Li, Y. Hu, A. Li, J. Lin, K. Hsieh, Z. Schneiderman, P. Zhang, Y. Zhu, C. Qiu, E. Kokkoli, T. H. Wang and H. Q. Mao, *Nat. Commun.*, 2022, **13**, 5561.
- 235 K. A. Risma, K. M. Edwards, D. S. Hummell, F. F. Little, A. E. Norton, A. Stallings, R. A. Wood and J. D. Milner, *J. Allergy Clin. Immunol.*, 2021, **147**, 2075–2082.
- 236 B. Bozkurt, I. Kamat and P. J. Hotez, *Circulation*, 2021, **144**, 471–484.
- 237 D. V. Parums, *Med. Sci. Monit.*, 2021, **27**, e932899.
- 238 E. Rista, A. Strakosha, K. Saliq, F. Ymeri and M. Ikonomi, *Cureus*, 2023, **15**, e33938.
- 239 A. Flemming, *Nat. Rev. Immunol.*, 2021, **21**, 72.



- 240 Y. Chen, Z. Xu, P. Wang, X. M. Li, Z. W. Shuai, D. Q. Ye and H. F. Pan, *Immunology*, 2022, **165**, 386–401.
- 241 Q. Cheng, T. Wei, L. Farbiak, L. T. Johnson, S. A. Dilliard and D. J. Siegwart, *Nat. Nanotechnol.*, 2020, **15**, 313–320.
- 242 T. Suzuki, Y. Suzuki, T. Hihara, K. Kubara, K. Kondo, K. Hyodo, K. Yamazaki, T. Ishida and H. Ishihara, *Int. J. Pharm.*, 2020, **588**, 119792.
- 243 J. K. Tom, T. J. Albin, S. Manna, B. A. Moser, R. C. Steinhardt and A. P. Esser-Kahn, *Trends Biotechnol.*, 2019, **37**, 373–388.
- 244 L. Miao, L. Li, Y. Huang, D. Delcassian, J. Chahal, J. Han, Y. Shi, K. Sadtler, W. Gao, J. Lin, J. C. Doloff, R. Langer and D. G. Anderson, *Nat. Biotechnol.*, 2019, **37**, 1174–1185.
- 245 M. Ripoll, M. C. Bernard, C. Vaure, E. Bazin, S. Commandeur, V. Perkov, K. Lemdani, M. C. Nicolaï, P. Bonifassi, A. Kichler, B. Frisch and J. Haensler, *Bio-materials*, 2022, **286**, 121570.
- 246 V. Francia, R. M. Schiffelers, P. R. Cullis and D. Witzigmann, *Bioconjugate Chem.*, 2020, **31**, 2046–2059.
- 247 K. Van der Jeught, S. De Koker, L. Bialkowski, C. Heirman, P. Tjok Joe, F. Perche, S. Maenhout, S. Bevers, K. Broos, K. Deswarte, V. Malard, H. Hammad, P. Baril, T. Benvegno, P. A. Jaffrès, S. A. A. Kooijmans, R. Schiffelers, S. Lienenklaus, P. Midoux, C. Pichon, K. Breckpot and K. Thielemans, *ACS Nano*, 2018, **12**, 9815–9829.
- 248 G. Anderluzzi, G. Lou, S. Woods, S. T. Schmidt, S. Gallorini, M. Brazzoli, R. Johnson, C. W. Roberts, D. T. O'Hagan, B. C. Baudner and Y. Perrie, *J. Controlled Release*, 2022, **342**, 388–399.
- 249 J. L. Schnyder, H. M. Garcia Garrido, C. A. De Pijper, J. G. Daams, C. Stijnis, A. Goorhuis and M. P. Grobusch, *Travel Med. Infect. Dis.*, 2021, **41**, 102007.
- 250 L. Van Hoecke, K. Roose, M. Ballegeer, Z. Zhong, N. N. Sanders, S. De Koker, X. Saelens and S. Van Lint, *Mol. Ther.–Nucleic Acids*, 2020, **22**, 373–381.
- 251 T. Mao, B. Israelow, M. A. Peña-Hernández, A. Suberi, L. Zhou, S. Luyten, M. Reschke, H. Dong, R. J. Homer, W. M. Saltzman and A. Iwasaki, *Science*, 2022, **378**, eabo2523.
- 252 A. Akinc, W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, K. N. Jayaprakash, M. Jayaraman, K. G. Rajeev, W. L. Cantley, J. R. Dorkin, J. S. Butler, L. Qin, T. Racie, A. Sprague, E. Fava, A. Zeigerer, M. J. Hope, M. Zerial, D. W. Sah, K. Fitzgerald, M. A. Tracy, M. Manoharan, V. Koteliansky, A. Fougerolles and M. A. Maier, *Mol. Ther.*, 2010, **18**, 1357–1364.
- 253 E. Sadauskas, H. Wallin, M. Stoltenberg, U. Vogel, P. Doering, A. Larsen and G. Danscher, *Part. Fibre Toxicol.*, 2007, **4**, 10.
- 254 R. Zhang, R. El-Mayta, T. J. Murdoch, C. C. Warzecha, M. M. Billingsley, S. J. Shepherd, N. Gong, L. Wang, J. M. Wilson, D. Lee and M. J. Mitchell, *Biomater. Sci.*, 2021, **9**, 1449–1463.

